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ABSTRACT 
 
Fetal stress has been linked to adult atherosclerosis, obesity, and diabetes.  
Epidemiology studies have associated fetal exposure to maternal smoking and post-natal 
exposure to environmental tobacco smoke (ETS) with increased asthma risk.  We tested 
the hypothesis, in a mouse model of asthma, that ETS exposure in utero alters airway 
function and respiratory immune responses in adult offspring.  
Pregnant BALB/c mice were exposed daily to ETS or filtered air (AIR). Neonatal 
gene expression was assessed.  Offspring inhaled aerosolized ovalbumin (OVA) or saline 
in weeks 7-8. Regardless of whether they inhaled OVA or saline, mice were sensitized by 
OVA injections in weeks 11 and 13 followed by OVA aerosol challenge in weeks 14-15. 
At weeks 6, 10, and 15, we assessed OVA-specific serum immunoglobins, 
bronchoalveolar lavage cells and cytokines, lung and nasal histopathology, lung gene 
expression, and airway hyperresponsiveness (AHR).   
Neonatal mice demonstrated slight but potentially critical differences in gene 
expression related to their exposure to ETS in utero.  At 6 weeks, there were no 
significant differences between mice exposed to ETS in utero and those exposed to AIR 
in utero.  At 10 weeks, following OVA aerosol, mice exposed to ETS in utero displayed 
greater AHR than mice exposed to AIR in utero ( = 0.05), unaccompanied by changes 
in histopathology, cytokine profile, or antibody levels.  However, there were significant 
differences in gene expression between these 10 week groups.  At 15 weeks, mice that 
had inhaled saline in weeks 7-8 developed airway inflammation: eosinophilia ( = 0.05), 
IL-5 ( = 0.05) and AHR ( = 0.05) were greater in mice exposed to ETS in utero vs. 
mice exposed to AIR in utero.  Mice that had inhaled OVA in weeks 7-8 demonstrated no 
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airway inflammation after sensitization and challenge and those exposed to ETS in utero 
had suppressed immune and inflammatory responses.  Consistent with other findings at 
15 weeks, there were significant differences in gene expression between mice receiving 
ETS exposure in utero and those receiving AIR exposure in utero. 
 ETS exposure in utero exacerbates subsequent adult responses to initial allergen 
exposure and causes altered gene expression, especially with additional lung perturbation.   
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CHAPTER 1 
 ENVIRONMENTAL INFLUENCE ON THE INCREASE IN INCIDENCE OF HUMAN 
ASTHMA 
 
There has been a notable increase in the incidence and prevalence of asthma and allergy 
within the world population during the past fifty years (Mannino et al. 2002; Pearce et al. 2000; 
Sunyer et al. 1999).  Although these increases have been worldwide, the majority of the changes 
are found in industrialized, or developed, nations (Rottem et al. 2005).   These increases have 
occurred over such a brief period in time that even a dominant gene would not have had time to 
spread through the human population.  Therefore, attention has focused on global environmental 
changes that might be responsible for increases in asthma and allergy.   
Environmental exposures in developed versus non-developed regions of the world are of 
particular interest.  Many theories have evolved around perturbations to the developing immune 
system, including the incrimination of vaccines, decreased parasite exposure, decreased viral 
infections, and increased environmental pollutants (Woodruff and Fahy 2001).  To date, no clear 
causative discovery has been made.  Specifically, little has been done on the ability of inhaled 
environmental contaminants to interact with susceptibility genes and thus alter the development 
of asthma and allergy. 
Typically, as developed nations continue to mature, ambient environmental pollution 
becomes a concern and measures are taken to reduce environmental pollution.  As a result, 
ambient environmental pollution has declined markedly in industrialized nations (Heinrich et al. 
2000; Laden et al. 2006).  However, the identity and character of remaining environmental 
contaminants are still an issue.  Remaining pollutants (e.g., those arising from combustion of 
fossil fuels, manufacture of synthetic materials, and use of cigarettes) may be of a more synthetic 
or complex nature.  The wide spread use of these materials has occurred only within the last one 
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hundred years with the major increase within the past fifty years.  This coincides with the 
changes and progression seen in asthma and allergy.   
Environmental tobacco smoke (ETS) is “second-hand” smoke.  It is composed of 
approximately 90% sidestream smoke and 10% exhaled mainstream smoke.  Sidestream smoke 
is smoke arising from the burning end of the cigarette.  This smoke does not pass through the 
cigarette filter and is inhaled as a component of the ambient air.  In the United States, the vast 
majority of cigarettes contain an attached cellulose fiber filter. Mainstream smoke is drawn 
through the cigarette, through this filter, and directly into the airway in a concentrated form.  
However, exhaled mainstream smoke has been treated by a sophisticated and efficient filter prior 
to inhalation and has been further filtered by the respiratory components responsible for the 
continuous treatment of inhaled air.  By convention, sidestream smoke is usually used as a 
surrogate for ETS, or “second-hand” smoke.  We maintain this convention in our studies.   
ETS has been examined by many researchers and has been associated with exacerbation 
of adult asthma and allergy symptoms (Jaakkola et al. 2003; Jindal et al. 1994).  A number of 
studies have evaluated the role of ETS in initiation of allergy or asthma in the perinatal period 
(DiFranza et al. 2004; Hong et al. 2003; Jaakkola et al. 2006).  Previously, we conducted studies 
concerning the health effects of inhaled ETS, including ETS exposure effects on development of 
asthma and allergy in adult mice and cardiovascular disease in adult mice that were exposed to 
ETS in utero.  The latter studies indicated that ETS exposure in utero promoted the development 
of atherosclerotic plaques in adults (Yang et al. 2004).  In contrast, adult ETS inhalation did not 
alter the response of mice to subsequent allergen exposure (Bowles et al. 2005).   
Findings from in utero studies are consistent with the ideas of David Barker (Barker 
2002) and the resultant developmental “Barker Hypothesis”.  Although Barker initially described 
a relationship between prenatal, or maternal, malnutrition and subsequent adult cardiovascular 
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disease, the hypothesis has been extended to include other common chronic adult diseases and 
other developmental perturbations.  The tenets of the hypothesis include; (1) there is a 
disturbance in the normal uterine environment during a critical period of gestation; (2) the 
developing fetus has plasticity, or the ability to adapt to the disturbance, in a way to maximize 
the chances for survival; (3) beyond a critical point, fetal programming occurs thereby limiting 
the ability of the fetus to return to pre-disturbance responses; (4) upon chronic exposure to a 
“normal” environment the adult is unable to mount “normal” responses and therefore chronic 
adult disorders develop (hypertension, insulin resistance, hypercholesterolemia, and 
hyperuricemia).  We hypothesize that in utero environmental toxin exposures can serve to 
disturb the “normal” uterine environment and that the chronic disorders that can develop include 
allergy and asthma.  To test this hypothesis, we conducted in utero exposures of pregnant mice to 
ETS and followed the responses of their offspring to allergen exposure and challenge. 
This dissertation describes studies involving ETS exposure in utero and the subsequent 
effect on immune responses to allergen in the adult offspring.  The dissertation is divided into 
five chapters.  Chapter one is this introductory chapter.  The second chapter addresses the 
rationale, material, methods, and outcome of the non-genetic findings of ETS exposure in utero, 
before and after allergen exposure in the adult offspring.  Chapter three describes the rationale, 
material, methods, and findings of the gene expression studies of the mice at the final time point 
described in chapter two (15 weeks of age) and evaluates the correlation of these findings with 
the physical findings at that same time point.  Chapter four examines the gene expression 
findings at the other time points examined in chapter two and relates those findings to the 
physical findings for those time points.  The final chapter is a concluding chapter with critical 
and forward-looking remarks based on this study.  
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The majority of this information has been previously published in peer-reviewed journals 
as two large manuscripts, one covering the information from chapter two (Penn et al. 2007) and 
the other detailing the information from chapter three (Rouse et al. 2007).  Chapter four contains 
data that have not been published as of this writing.  In the final chapter, concluding remarks 
summarize the findings of all of these studies and the implications of these findings for present 
and future research.  The potential of other methodologies and techniques in, and new or 
alternate directions for, this research is also discussed. 
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CHAPTER 2 
EXPOSURE TO ENVIRONMENTAL TOBACCO SMOKE IN UTERO POTENTIATES 
ADULT RESPONSES TO ALLERGEN IN BALB/c MICE
1
 
 
INTRODUCTION 
The incidence of asthma has escalated over the past twenty years.  Increasingly, initial 
asthma episodes are observed early in life (Weiss 1998; Holt 1998).  In 2004, nearly 30% of the 
thirty million diagnosed asthmatics in the United States were under 18 years of age.  The highest 
asthma prevalence rate (148/1000) exists in 5-17 year-olds (American Lung Association 2006).  
Despite the often early onset of this disease, chronic adult asthmatics comprise the majority of 
asthma patients.   
 Stresses in the fetal environment can promote early onset of chronic adult diseases.  
Initial epidemiological studies related maternal nutritional deficits to low live birth weights and 
to premature cardiovascular disease in adult human offspring (reviewed in Barker 2002). In 
humans, neurological response to fetal stress has been recently reviewed (Amiel-Tison et al. 
2004). In experimental studies, fetal anemia in sheep (Davis et al. 2005) and hypoxia in pregnant 
rats (Li et al. 2004) have resulted in chronic disease in adult offspring.  In pregnant mice, viral 
infection (Niklasson et al. 2006), pesticide treatment (Cory-Slechta et al. 2005), and 
environmental tobacco smoke (ETS) exposure (Yang et al. 2004) have also resulted in chronic 
adult disease in offspring. 
  Exposure to ETS has been associated with exacerbated asthmatic responses in children 
(Gilliland et al. 2000; Lindfors et al 1999; Mannino et al. 2001).  Altered lung function, 
increased risk of asthma, and persistent lung function deficits in children have been linked with 
in utero exposure to maternal smoking and/or post-natal exposure to ETS (Gilliland et al. 2000; 
                                                 
1
 This chapter was published (non-copyright) in Environmental Health Perspectives 115(4): 548-555.  
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2001; 2003; Li et al. 2000; Zlotkowska and Zejda, 2005).  The synergistic action of tobacco 
smoke exposure with sensitization to non-tobacco allergens may increase the prevalence of 
allergy and asthma (Oryszczyn et al. 2000). Detailed experimental studies focused on pro-
asthmatic responses resulting from in utero ETS exposure combined with post-natal exposure to 
non-tobacco antigens have not been reported.  
In rodent models of allergic asthma, ovalbumin (OVA) is a commonly employed antigen 
for eliciting allergic responses.  Sensitization by intraperitoneal (i.p.) injection, followed by 
inhalation challenge with OVA elicits expansion of the T helper-2 (Th2) lymphocyte population.  
Production of Th2 cytokines follows, leading to airway hyperresponsiveness (AHR) and 
inflammation characterized by eosinophilia and OVA-specific immunoglobin E (IgE; Zhang et 
al. 1997). 
This sensitization/challenge protocol fails to mimic the typical human experience of 
aerosol-only sensitization and challenge (Bice et al. 2000; Persson et al. 1997).  However, 
aerosol-only OVA exposure of mice results in little or no OVA-specific serum IgE, and no 
eosinophilic inflammatory response.  This has been attributed to the induction of immunological 
tolerance specifically affecting IgE production (Astori et al. 2000; Holt et al. 1981; McMenamin 
and Holt 1993; Seymour et al. 1998).  Interleukin (IL)-10 from regulatory T cells in the lung 
(Akbari et al. 2001) favors the production of IgG1 antibodies and inhibits isotype switching to 
IgE (Jeannin et al. 1998).  This, combined with the induction of T cell tolerance (Buer et al. 
2005), protects most individuals from developing allergic airway diseases to commonly 
encountered allergens (Tsitoura et al. 2000). While genetic polymorphisms and underlying 
regulatory faults in IL-4 and IL-13 production can impair this safety mechanism (Heinzmann et 
al. 2000; Howard et al. 2001; Izuhara et al. 2000; Seah et al. 2001; Shirakawa et al. 2000;), 
environmental exposures might also contribute to loss of airway tolerance. 
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We designed experiments to simulate the respiratory consequences to offspring of 
pregnant, non-smoking women exposed daily to ETS. We combined daily ETS exposure of 
pregnant BALB/c mice with post-natal OVA inhalation to test the hypothesis that ETS exposure 
in utero can alter post-natal respiratory and immune responses to non-tobacco allergens.  
We posed the following questions: 
Is exposure to ETS in utero sufficient to: 
compromise respiratory responses in young mice? in adults? 
promote cytokine production in OVA-exposed mice?  
influence AHR or lung histopathology following OVA provocation? 
interfere with establishment of aerosol tolerance to OVA or with production of 
OVA-specific antibodies? 
MATERIAL AND METHODS 
Animal Protocols 
  
We housed and handled BALB/c mice (Harlan, Indianapolis, IN) according to the NIH 
Guide for the Care and Use of Laboratory Animals.  The LSU IACUC approved all animal 
procedures, guaranteeing humane treatment and alleviation of suffering.  Mice, on a 12-hour 
light/dark cycle, had food and water ad libitum except when in the exposure chambers.  We 
began breeding eight-week old mice (1 male/ 2 females) the evening prior to initiation of ETS 
exposure.  After exposures ended (day 19), we housed pregnant mice in separate cages until 
weaning (day 21 after birth).  A barbiturate solution (Beuthanasia-D, Schering-Plough, 
Kenilworth, NJ) was used via intraperitoneal injection (0.2 ml per mouse) for all sacrifices. 
ETS Exposures 
 
Sidestream smoke, which comprises ~90% of ETS, served as a surrogate for ETS (Penn 
and Snyder 1993, Bowles et al. 2005). A 30-port smoking machine (AMESA Technologies, 
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Geneva, Switzerland) generated smoke from 2R4F filtered research cigarettes (Univ of KY, 
Lexington, KY).  We diluted ETS with HEPA-filtered air (AIR) to establish a suspended particle 
load of 10mg/m
3
.  A MIRAN sapphIRe infrared spectrometer (The Foxboro Co., Foxboro, MA) 
and a DustTrak particle monitor (STI, St. Paul, MN) continuously monitored carbon monoxide 
and total suspended particle levels, respectively, in exposure chambers.  Gravimetric analyses 
were performed every 2 hrs by weighing 0.45mm membrane filters (Gelman, Ann Arbor, MI) 
through which measured amounts of smoke had passed.  We exposed 8-week old mated mice to 
ETS or AIR (14 air changes/hr, 5 hr/day, 19 consecutive days) in 1.3m
3 
stainless steel and 
plexiglass dynamic exposure chambers (T
o
=71
o 
± 1.5
o
F; RH=53 ± 3%).  No offspring were 
exposed to ETS after birth. 
Aerosol Exposures 
 
We exposed mice in a 16-compartment, 16.7-liter plexiglass inhalation exposure chamber 
to aerosolized sterile saline or 1% (w/v) OVA (Grade V >98% pure; Sigma-Aldrich, St. Louis, 
MO) in saline (20 min/day; 10 days; 7-8 weeks of age).  A flow rate of 4L/min was maintained 
through an Airlife sidestream high-efficiency nebulizer (Cardinal Health, Dublin, OH).   
OVA Sensitization/Challenge 
  
 We sensitized mice to OVA by (i.p.) injections (80 µg OVA in 2.0 mg alum), one each at 
11 and 13 weeks of age.  OVA challenge included three 20-minute inhalation exposures to 1% 
OVA in saline, every other day at 14 weeks, plus  a 20-minute exposure one day before sacrifice 
at 15 weeks.  
Bronchoalveolar Lavage (BAL) Cell and Fluid Collection 
 
Following euthanasia, we lavaged the right lung of each mouse 4X with 0.3 ml warm 
PBS  and re-suspended the centrifuged BAL cell pellet in PBS for BAL differential counts (200 
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cells).  Smears were stained with a modified Wright's stain. The BAL supernatant was stored at -
80°C for cytokine analyses.  
Creation of Standard Sera for Isotype-specific ELISAs 
 
We pooled and assayed sera from sensitized/challenged BALB/c mice for OVA-specific 
IgG1, IgG2a, and IgE by isotype-specific ELISA at varying dilutions (IgG1 1:10000; IgG2a 1:100; 
IgE 1:10).  The pooled sera constituted a standard in subsequent isotype-specific ELISAs on test 
sera.  The isotype-specific optical density (O.D.) value from the isotype standard was set as one 
ELISA Unit (EU).    
OVA-specific IgGl, IgG2a and IgE ELISA  
 
We used isotype-specific ELISAs to quantitate OVA-specific antibody levels in sera 
(Seymour et al. 1997) from blood obtained at sacrifice.  For IgG1 and IgG2a, OVA-coated (100 
µl/well of 0.1% OVA) 96-well flat bottom plates (Fisher, Pittsburgh, PA) captured OVA-specific 
antibodies.  Horseradish peroxidase-conjugated (HRP) rat anti-mouse IgGl or IgG2a antibodies 
(BD-Pharmingen, San Diego, CA) marked captured antibody.  For OVA-specific IgE detection, 
monoclonal rat anti-mouse IgE (5ug/ml in PBS; BD-Pharmingen) coated (100ul/well) 96-well 
Immulon4 plates (Thermo Electron Corp., Waltham, MA) captured serum IgE.  Biotinylated-
OVA (2.5mg/ml; Pierce EZ-Link LC; Pierce, Rockford, IL) and HRP-streptavidin (Pierce) 
marked captured OVA-specific antibody.  For all ELISAs, TMB substrate (100ul/well) detected 
marked antibodies.  We used a standard ELISA reagent kit (OptEIA Reagent Set B, BD-
Pharmingen) and converted O.D.450 readings of the samples to EU. 
Histopathological Analysis of Lungs 
  
 Following BAL collection, we perfused lungs with 0.3 ml of freshly prepared 0.02M 
periodate-0.1M lysine-0.25% paraformaldehyde (PLP) fixative in phosphate buffer (pH 7.4), 
then excised and stored the lungs in PLP for 24-48 hr.  We sectioned the cranial, middle and 
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caudal lobes of the right lung along the plane of each lobar bronchus.  Following post-fixation in 
70% ethanol, we embedded samples in paraffin and dehydrated them directly in graded alcohols 
to eliminate further exposure to formaldehyde.  We stained 3-4 µm sections with hematoxylin 
and eosin.  We used a seven category weighted scoring system (bronchus-associated lymphoid 
tissue, lymphocytes, plasma cells, eosinophils, neutrophils, mucus metaplasia and total 
cellularity) for histopathological evaluation of lung sections (Bowles et al. 2005). A board-
certified veterinary pathologist, blinded to the treatments, evaluated histopathological samples.  
A higher score (maximum score = 25) is indicative of greater tissue responsiveness. 
Histochemical Analysis of Nasal Tissue 
 
  We fixed heads in buffered-neutral formalin then decalcified them for 3 days in 15% 
formic acid before sectioning (Bahnemann et al. 1995).  A pathologist, blinded to the treatments, 
scored nasal sections for inflammation by cell type and epithelial changes, according to the type 
of epithelium (squamous, respiratory, and olfactory).  
Cytokine Quantitation in BAL Fluid 
 
   We used a fluorescence-based murine Th1/Th2 cytometric bead array assay (BD-
Pharmingen) to analyze aliquots of BAL supernatants on a BD FACSCaliber instrument.   The 
cytokines included in the assay were IL-2, IL-4, IL-5, TNF- and IFN-.  Their limits of 
detection were 5.0, 5.0, 5.0, 2.5 and 6.3pg/ml, respectively.  A single bead assay for IL-13 had 
limits of detection of 7.3pg/ml. 
Pulmonary Function Testing 
 
We assessed AHR in unrestrained mice by whole body plethysmography (Buxco, Troy, 
NY).  Data were expressed as a dimensionless value, Penh, or „enhanced pause‟ (Hamelmann et 
al. 1997a).  Following acclimation and aerosol saline exposure, we challenged mice with graded 
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doses (1.56-50.0 mg/ml) of nebulized methacholine (Sigma-Aldrich, St. Louis, MO) to assess 
AHR.  We recorded post-exposure Penh values over 5 minutes for each dose.   
While some concern has been expressed regarding the limitations of Penh measurements 
obtained via unrestrained plethysmography (Lundblad et al. 2002), there are many reports of 
strong correlations between increases in Penh values and bronchoconstriction, demonstrating that 
Penh serves as a reliable monitor of changes in lung mechanics (Delorme and Moss 2002; 
Hamelmann et al. 1997b; Singh et al. 2003).  
Statistical Analysis 
 
 We used the SAS statistical package (version 9.1.3; SAS Institute, Inc., Cary, NC) GLM 
procedure for all analyses.  In addition, where appropriate, we conducted an analysis of variance 
(ANOVA) by sampling time with various endpoints (BAL cells, histopathology scores, cytokine 
levels) as the response variables, and treatment, gender, and treatment-gender interaction as 
effects in the model.   We analyzed antibody data by a one-way ANOVA across treatment 
groups and plethysmograph data in an ANOVA on repeated measures.  In considering limits of 
detection, we ranked cytokine data and carried out a Kruskal-Wallis test (one-way ANOVA) on 
the ranks.  When the overall model indicated significance, we conducted post hoc pair-wise 
comparisons with Tukey‟s HSD test for main effects comparisons (Siegel 1956; Steele and 
Torrie 1980).  Pair-wise comparisons of significant interaction effects were conducted with t-
tests of least square (adjusted) means.  In all cases, we considered comparisons significant at  = 
0.05. 
To test the trend and relationship of one treatment group to another, we paired (blocked) 
the means of the various response variables and compared the two treatment groups with respect 
to these paired mean values.  The null hypothesis was that the treatment groups were the same 
based on the paired comparisons.  We used the Wilcoxon matched-pairs test, Pearson correlation 
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test, and a regression analysis on the matched groups to examine the potential trend.  We 
considered all analyses significant at  = 0.05 (Neter and Wasserman 1974).       
Exposure and Sampling Schedules 
 
We randomly assigned mated females to gestational ETS or AIR exposure groups.  At 
weaning, mice were segregated by sex with no more than 4-5 mice per cage.  We sacrificed 
groups of 6-week old mice exposed to ETS or AIR in utero to determine effects of ETS exposure 
in utero on lung responses of young mice.  Half the remaining mice inhaled OVA (EO, AO) 
aerosol at 7-8 weeks of age.  The other half inhaled saline aerosol (ES, AS).   Each of these 
groups contained 35 to 39 mice representing 6 to 10 litters.  We sacrificed mice in each group at 
10 weeks of age to determine the effects of in utero ETS exposure, plus subsequent OVA 
inhalation, on lung responses of young adult mice.  We sacrificed the remaining mice, following 
OVA-sensitization and -challenge, at 15 weeks of age to determine the effects of in utero ETS 
exposure on responses to OVA sensitization (ESO, ASO) and OVA tolerance (EOO, AOO).  We 
analyzed antibody levels, BAL cytology and Th1/Th2 cytokine levels, lung and nasal 
histopathology, and pulmonary function at all time points. 
RESULTS 
Forty to fifty percent of ETS and AIR females had litters. There were no significant 
differences in delivery rate or litter size between ETS and AIR dams. However, in utero ETS 
offspring were of slightly lower birth weight and experienced a higher mortality rate between 
birth and three weeks of age than did in utero AIR offspring (12% vs. 2%,  = 0.05).  Thereafter, 
survival rates were similar and any inequity in weight or growth rate was lost.  In both groups, 
the male to female offspring ratio was approximately 1:2.  At weaning, offspring exposed to ETS 
in utero totaled 89 from 19 litters and offspring exposed to AIR in utero totaled 94 from 19 
litters.   
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We detected no upper respiratory tract changes, including evidence of inflammation or 
congestion, in any treatment groups at any time point during this study, as determined by 
evaluation of nasal histopathology.  We determined no gender differences in responses of mice 
exposed in utero to ETS and subsequently to OVA.  There are no equivalent experimental 
asthma studies with which to compare gender responses directly, since the ETS/OVA exposure 
schedule we followed has not been reported previously in a mouse model of asthma.  There are, 
however, reports of gender differences with regard to asthma endpoints, following post-natal 
ETS and OVA exposures in Balb/c mice (Melgert et al. 2005; Seymour et al. 2002).  Humans 
display gender differences with regard to asthma endpoints, as well.  More adult females than 
males have asthma, although this relationship is reversed in children (American Lung 
Association 2006).  Mortality due to asthma is higher among human females than among males.  
SIX WEEKS OF AGE 
Results 
Results from this time point (Figure 2.1) were analyzed to determine whether ETS 
exposure in utero altered basic lung development in either structure or function.  No significant 
differences were noted in antigen specific antibody levels, BAL cell counts, BAL cytokines, or 
 
Figure 2.1:  Six week timeline demonstrates the exposure of pregnant mice for nineteen 
consecutive days (-19d to -1d) to either ETS or HEPA-filtered air (AIR) followed by birth 
one to two days later (0d).  Offspring received no further exposure to ETS or AIR, were 
weaned at 3 weeks of age, and sacrificed at 6 weeks of age. 
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histopathology.  Exposure to ETS in utero, without any subsequent treatment, had no overall 
effect on pulmonary function (the entire curves are not significantly different), although at the 
two highest methacholine doses a significant AHR increase (p≤ 0.017) was noted in ETS mice 
(Figure 2.2).  
Discussion 
 
Results from six-week old mice indicate that ETS exposure in utero, without further lung 
challenge, has no observable effect on pulmonary function or histology.  The only significant 
finding at this age is elevated AHR in ETS mice at the two highest methacholine challenge 
doses.  These points are insufficient to produce a significant difference in the total response 
curve.  However, they may reflect an ETS-induced AHR sensitivity that becomes more apparent 
with additional lung stress or challenge.   
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Figure 2.2:  Mice received graded doses (1.56-50 mg/ml) of nebulized methacholine.  
Airway hyperresponsiveness (AHR) to bronchoconstriction is captured in the Penh value 
as determined by non-invasive, whole-body plethysmography for increasing doses of 
methacholine (bronchoconstrictor).  Low doses demonstrate no differences, but at the two 
highest doses there were significantly different responses (p=0.017 at 25 mg/ml and p<0.001 
at 50 mg/ml).  (*) significant difference p≤0.017; these points were not sufficient to create a 
significant difference in overall response curves. 
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 Aerosol OVA exposure in the absence of adjuvant results in OVA-specific aero-tolerance 
to future OVA aerosol exposure.  Data from this time point were used to investigate whether 
ETS exposure in utero would alter immune responses to OVA and overcome the establishment 
of OVA tolerance.  Timing of exposures is demonstrated in Figure 2.3.  At 10 weeks of age, EO 
and AO mice had consistently differing OVA- specific antibody profiles,  IgG1  (EO > AO)  and 
IgG2a (AO > EO).   These differences, however, were not significant for either isotype (data not 
presented).  We detected no OVA-specific IgE in sera of OVA-aerosol exposed mice.  As 
expected, we detected no OVA-specific IgG1, IgG2a, or IgE in control mice, regardless of 
whether their exposure in utero was to ETS (ES) or AIR (AS).  
 
TEN WEEKS OF AGE 
 
Figure 2.3:  Ten week timeline duplicates the six-week timeline through birth and weaning 
then deviates with allergen (OVA 1%) or saline aerosol exposures (20 minutes per day for 
10 days) at seven and eight weeks of age followed by sacrifice at ten weeks of age.  
OVA=ovalbumin. 
 
Results 
 With the exception of TNF, all cytokine levels were below limits of detection for all 
groups at 10 weeks.  TNF was significantly higher (p < 0.05; data not presented) in AO mice 
compared to other groups.  Aerosol OVA exposure at 7 - 8 weeks of age had little overall effect 
on BAL cell distribution at 10 weeks.  As at 6 weeks of age, BAL cells in all groups were mostly 
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(94 - 100%) mononuclear cells.  Lung histopathology scores were low, ranging from 6.47 - 7.15.  
There were no significant differences between any groups in BAL cell distributions or lung 
histopathology.  
 Ten-week old AO mice demonstrated significantly increased AHR compared to AS mice 
(Figure 2.4) at methacholine levels ≥ 12.5 mg/ml.  This response was amplified in mice exposed 
to ETS in utero.  Ten-week old EO mice exhibited significantly elevated AHR compared to all 
other groups, at  methacholine levels > 6.25 mg/ml.   At the highest methacholine concentration 
(50 mg/ml), the AHR of EO mice was 2 – 4X greater than that of other groups.  Overall response 
curves were not significantly different between ES and AS mice.  However at the highest 
methacholine level, ES mice had increased AHR (p < 0.0001) relative to AS mice.  
 
Figure 2.4:   Mice received graded doses (1.56-50 mg/ml) of nebulized methacholine.  AHR, 
expressed as Penh values, was determined by non-invasive, whole-body plethysmography.  
ETS exposure in utero increased AHR in 10-week old mice; (*) significant difference 
between all groups; (**) significant difference between AS and both AO and ES; p<0.0001; 
bars represent mean ± SE.  
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Discussion 
At 10 weeks of age, groups of both ETS and AIR mice were exposed to aerosol OVA in 
the absence of any adjuvant, including LPS, to produce mice that were tolerant to airway 
inflammation by OVA sensitization and challenge.  The antibody profiles of these animals were 
as expected. There were significant OVA-specific antibody responses (IgG1 and IgG2a) 
indicating recognition and allergen-specific activation, but no indication of significant effector 
response (eosinophilia, mucus hyperplasia, cytokine elevation, or OVA-specific IgE).  These 
findings are consistent with prior studies (Holt et al. 1981; Swirski et al. 2002).  As previously 
reported (Renz et al. 1992), AHR was significantly elevated in OVA mice relative to non-OVA 
mice.  However, the AHR of EO mice was increased significantly relative to AO mice, 
demonstrating an ETS-dependent exacerbation of AHR to initial allergen exposure.  This 
exacerbation was independent of classical inflammatory or Th2 endpoints, an occurrence that has 
been previously described (Barrett et al. 2002).  As was the case in 6-week old ETS mice, 10 
week-old ES mice demonstrated significant increase in AHR compared to AS mice at the highest 
methacholine dose.  Again, this was not sufficient to create a significant difference in the total 
response curve. 
FIFTEEN WEEKS OF AGE 
 
Results 
 
 The OVA sensitization and challenge protocol used at fifteen weeks of age, and shown in 
Figure 2.5, elicits systemic and local allergic responses to OVA, thereby establishing an asthma 
phenotype.   This protocol was used in OVA-tolerant mice (OVA aerosol at 7-8 weeks of age) to 
determine whether ETS exposure in utero overcomes OVA-tolerance induced by OVA aerosol 
exposure.  This same protocol was used in mice without prior OVA exposure (saline aerosol at 
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7-8 weeks of age) to examine whether ETS exposure in utero enhanced or otherwise altered 
immune response to OVA sensitization and challenge. 
 
 
 
Figure 2.5:  Fifteen week timeline mirrors the ten-week timeline through the seven- to 
eight-week of age aerosol exposures after which it deviates, with OVA sensitization and 
challenge exposures beginning with i.p. injections at eleven and thirteen weeks of age 
followed by aerosol exposures every other day at fourteen weeks of age and sacrifice at 
fifteen weeks of age.  
 
 
 We analyzed all fifteen week-old mice for the effects of in utero ETS exposure on 
responses to the OVA sensitization and challenge.  There were no significant differences in 
OVA-specific IgG1, IgG2a and IgE levels between groups of mice exposed to OVA for the first 
time (ASO and ESO) or between groups previously exposed to OVA (AOO and EOO; Figure 
2.6).  In the former, there were significantly lower levels of OVA-specific IgG2a and significantly 
higher OVA-specific IgE levels than in the latter.   
 All measured cytokines were higher in ESO vs. ASO mice, though not significantly 
(Table 2.1).   IL-4, IFN and TNF were significantly lower in EOO vs. AOO mice.  Levels of 
IL-4, IL-5, IL-13, and TNF were significantly lower in EOO vs. ESO mice.    IL-13 and IL-5 
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consistently higher in mice exposed to OVA for the first time (ESO and ASO) than in mice 
previously exposed to OVA (EOO and AOO).  Levels of IL-2 did not differ between any groups. 
 
Figure 2.6:  ETS exposure in utero has no effect on OVA-specific serum antibody (IgG1, 
IgG2a, IgE) levels in 15-week old mice.  (*) indicates a significant difference from both ASO 
and ESO;  = 0.05; bars represent ± SE. 
 
 
Table 2.1:  ETS Exposure in Utero Alters BAL Cytokine Responses of 15-Week Old Mice 
 
Data were ranked to account for values below the limit of detection.  Ranked data were 
analyzed using a Kruskal-Wallis test (one-way ANOVA).  When significant, Tukey’s HSD 
test was used for post-hoc comparisons of effects.  For each cytokine, values marked (*) are 
significantly different from values marked (**);  = 0.05.  Values without an asterisk are 
not significantly different from any other value. 
 
 IL-13 IL-4 IL-5 TNFα IFNγ  IL-2 
AOO (n=21) 1.05* 42.76**   7.24* 31.45** 37.21** 9.07 
EOO (n=18) 1.00* 20.14*   1.17* 11.56* 18.36* 2.83 
ESO (n=14) 4.57**      48.82** 26.43** 31.96** 35.61 7.54 
ASO (n=19) 3.18 39.79** 18.37** 21.53 35.40 4.00 
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Figure 2.7:  ETS exposure in utero affects BAL cell differentials in 15-week old mice. A 
200-cell differential count was performed on BAL cells from each mouse in every group; 
(*) significant difference between all groups; (**) significant difference between EOO and 
both AOO and ASO; (***) significant difference between ESO and both AOO and EOO.  
Data was considered significant at α = 0.05; bars represent mean ± SE.  Values are 
proportion of total cell count. 
 
 
Eosinophil levels in BAL fluid were significantly higher in ESO and ASO vs. AOO and 
EOO mice (Figure 2.7).   Eosinophil and PMN levels were significantly lower in EOO vs. AOO 
mice.   Mononuclear cells accounted for > 96% of the BAL fluid cells in EOO mice.  There were 
no BAL cell differences between AOO and ASO mice. 
Increased lung inflammation was evident in both ESO and ASO mice (Figure 2.8).  Lung 
inflammation in mice previously exposed to OVA (EOO and AOO) was significantly reduced 
compared to that in mice exposed to OVA for the first time (ESO and ASO).   Again, the largest 
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difference was between ESO and EOO mice.  There were no differences between EOO and AOO 
or between ESO and ASO. 
   
Figure 2.8:  Inflammatory responses are most pronounced in ESO mice and least 
pronounced in EOO mice at 15 weeks.  Inflammation responses are reflected by 
perivascular and peribronchial cellular infiltrate, increased airway mucus production, and 
increased interstitial density.  Photomicrographs (100x) were from the median 
histopathology score mouse of each group. 
 
 
There was increased AHR, as expected, at methacholine levels from 12.5-50 mg/ml in 
mice exposed to OVA for the first time (ESO and ASO; Figure 2.9) compared to  mice  that  had  
previous  OVA-exposure  (EOO and AOO).     However, AHR in ESO mice was also 
significantly elevated compared to ASO mice.  Overall, the most striking differences in AHR 
were between the responsive ESO and the relatively non-responsive EOO mice.  The EOO mice 
also exhibited significantly attenuated AHR compared to AOO mice. 
4b. AOO 4a. ASO 
4c. ESO 4d. EOO 
 
23 
 
 
 
Figure 2.9:  ETS exposure in utero alters AHR in 15-week old Balb/c mice transiently 
exposed to methacholine. One day post-OVA challenge in week 15, methacholine 
provocation and non-invasive plethysmography were used to gauge AHR; (*) significant 
difference between ESO and all other groups (p<0.0001); (**) significant difference 
between ESO and both ASO and EOO (p≤0.013) and a significant difference between EOO 
and both AOO and ESO (p≤0.023); bars represent mean ± SE.  EOO differed significantly 
from ASO only at 25mg/ml methacholine.  This one point did not create a significant 
difference in overall response curves.   
 
As we analyzed our data, we noted what appeared to be trends in overall treatment group 
responses.  To further investigate this observation, we identified eleven endpoints that have a 
direct relationship to airway inflammation and/or Th2 responses (i.e., they all increase as 
inflammation and/or Th2 responses increase).  We used specific tests for trend to compare paired 
group means for these endpoint measures in mice exposed to ETS in utero and in those exposed 
to AIR in utero mice (Table 2.2).  Analyses confirmed significant trends in the relationship 
between ETS and AIR mice. 
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Table 2.2:  ETS Exposure in Utero Alters Initial Immune/Inflammatory Responses 
                   
 
             BAL Cytokines
a
          BAL       Methacholine
c
    Path
d
    Antibodies
e 
IL-13 IL-4 IL-5 TNFα     Eosb    12.5     25    50     Score   IgG1    IgE 
 
ESO versus ASO  
ESO 4.46    48.82 26.43 31.96    50.0%   2.86    4.90    7.68    19.3    1.28    0.20 
ASO 3.18    39.79 18.37 21.53    23.0%   1.74    3.20    4.04    17.7    0.46    0.18 
 
 
EOO versus AOO 
EOO 1.00    20.14 1.17 11.56      1.5%   1.51    2.31    4.05    10.4    0.90    0.08 
AOO 2.30    42.76 7.24 31.45    11.9%   2.28    4.00    7.62    12.8    1.00    0.13 
 
(a) Bronchoalveolar lavage (BAL) cytokines are ranked values; (b) Eos = eosinophils;(c) 
Airway hyperresponsiveness (AHR) is expressed as an index value, Penh, at three 
methacholine concentrations (12.5, 25, and 50 mg/ml); (d) Path score is a cumulative 
histopathological index value; (e) Serum antibody is expressed in ELISA units (EU). 
 
 
Pair-wise comparisons of group means at 15 weeks (Table 2.2) revealed significant 
differences for some responses of EOO vs. AOO mice (e.g., BAL differentials, cytokines, and 
AHR) and some responses of ESO vs. ASO (e.g., BAL differentials and AHR).  However, in all 
cases, responses were most attenuated for EOO mice and most pronounced for ESO mice.  
The Wilcoxon test on paired sign data confirmed that responses in EOO mice were 
uniformly lower (p = 0.001) than in AOO mice, indicative of a significant trend.  This was 
further strengthened by a Pearson correlation value of 0.96 and a ranked regression yielding an 
adjusted
 
R
2 
of 0.91.  This analysis supports the conclusion that exposure to ETS in utero 
suppressed responses to OVA sensitization/challenge in mice previously exposed to OVA.  The 
Wilcoxon test on paired sign data also demonstrated that responses in ESO mice were 
consistently higher (p = 0.001) across all data compared to responses in ASO mice.  This trend 
was further supported by a Pearson correlation value of 0.99 and a ranked regression yielding an 
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adjusted
 
R
2 
of 0.98.  These results support the conclusion that ETS exposure in utero exacerbates 
subsequent adult responses to initial allergen exposure. 
Discussion 
 
At 15 weeks of age, following OVA sensitization and challenge, ESO and ASO mice 
were the most responsive, as reflected by increased Th2 and inflammatory cytokines, respiratory 
eosinophilia, AHR, and OVA-specific IgE.  The EOO and AOO mice were OVA-tolerant with 
regard to cytokines, IgE, and airway inflammatory markers especially when compared to the 
ESO and ASO mice.  Overall, EOO mice were significantly less responsive than AOO mice in 
AHR, inflammatory cytokines, and BAL eosinophils and neutrophils. ASO mice exhibited 
classical markers of airway inflammation but no increased AHR.  AOO mice had no signs of 
airway inflammation but had increased AHR.  These results, combined with those of 10 week-
old EO mice, support the conclusion that adaptive and innate immune factors may be sufficient, 
but are not essential, for enhanced AHR in this murine asthma model.  In addition, the results at 
10 and 15 weeks demonstrate that ETS exposure in utero aggravates AHR following initial 
exposure to OVA, regardless of the route of OVA administration. 
ESO mice had enhanced initial responses to OVA sensitization and challenge while EOO 
mice had dampened responses upon re-exposure to OVA.  The reason for this response 
divergence is not intuitively obvious.  The enhanced responses measured in ESO mice at 15 
weeks of age reflect their initial response to OVA.  Due to the “memory” inherent in adaptive 
immune responses, the suppressed responses in EOO mice at 15 weeks of age are secondary 
responses that reflect the initial response to aerosolized OVA at 10 weeks of age.  Since that 
exposure was without adjuvant, establishment of tolerance to OVA was expected.  In the case of 
EOO, the decreased responsiveness at 15 weeks of age implies increased resistance to OVA 
sensitization and challenge.  Our data do not support a role for ETS exposure in utero in 
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determining the type (sensitization or tolerance) of immune response to allergen.  However, ETS 
exposure in utero appears to significantly influence the magnitude of response, which may 
increase sensitivity to allergen or severity of disease. 
Adult exposure to diesel exhaust particles, another major environmental combustion 
product, has been linked with increased incidence of allergies and asthma (Davies et al. 1998; 
Peterson and Saxon 1996), and rodent studies have  confirmed that diesel exhaust particles 
promote allergic and asthmatic immune responses (Nel et al. 1998; Pandya et al. 2002;). These 
adult studies suggest that ETS and possibly other environmental exposures do not cause immune 
deviation but have an adjuvant-like effect on immune response to allergen.  We demonstrate that, 
in addition to aggravating AHR, ETS exposure in utero promotes initial immune responses to 
allergen sensitization and challenge in adults (ESO vs. ASO).   
 Residual oil fly ash (ROFA) overcomes aerosol tolerance in young mice if the ROFA 
and OVA exposures are simultaneous (Hamada et al. 2000).  Similarly, concurrent 
administration of inhaled OVA and Th2-adjuvant prevented establishment of OVA-specific IgE 
tolerance (Hurst et al. 2001).  Once tolerance had been established, however, it could not be 
completely overcome by later simultaneous administration of OVA and the Th2 response-
provoking agents.  The latter finding is supported by our results, where tolerance resulting from 
OVA aerosol at 7-8 weeks of age persisted at least 8 weeks and was not overcome by ETS 
exposure in utero.  In fact, the dampened responses of adult EOO mice suggest increased 
resistance to sensitization and challenge.  These results are consistent with reports that smoking-
associated AHR increases can occur independent of changes in levels of Th2 cytokines and IgE 
(Robbins et al. 2005), and that smoking-allergen interactions may be allergen-specific (Jarvis et 
al. 1999).  
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While the mechanism underlying the ETS-mediated responses to initial OVA exposure 
has not been identified, preliminary results point to the involvement of arginase-1 (ARG1) in this 
process.  Up-regulation of ARG1 has been identified as an important step in the pathophysiology 
of asthma (Erdely et al. 2006; Zimmermann and Rothenberg 2006; Zimmerman et al. 2003). 
Nitric oxide (NO) production, which is vital for relaxation of airway smooth muscle cells, 
depends critically on the presence of adequate levels of arginine. Up-regulation of ARG-1 leads 
to increased catabolism of arginine, decreased NO production, and subsequently increased AHR.  
Consistent with this, PCR analysis revealed that ARG1 was up-regulated in lungs of ESO vs. 
EOO mice at 15 weeks of age (Rouse et al. 2007). 
The results of the 15-week study indicate that while ETS exposure in utero suppresses 
adult responses to repeated exposures of the same antigen (EOO), it also aggravates adult 
responses to initial antigen exposure  (EO at 10 weeks of age and ESO at 15 weeks of age).  If 
this heightened sensitivity extends beyond OVA to unrelated antigens, as seems likely, mice 
exposed in utero to ETS and then to other antigens as adults (e.g., Aspergillus, cockroach 
antigen, bacterial lipopolysaccharide or respiratory viruses) would have more exaggerated 
responses than mice not exposed in utero to ETS.  
Our studies were designed to address three distinct, but related issues in a mouse model 
of asthma: 1) whether there are any long-term, asthma-related consequences arising from 
exposure to ETS in utero, in the absence of any subsequent lung provocation; 2) what effects, if 
any, ETS exposure in utero has on adult responses to sensitization and challenge with an 
otherwise innocuous antigen (OVA); and 3) whether in utero exposure to ETS affects 
establishment of aerosol tolerance.  
Human epidemiological studies suggest that ETS exposure in utero may be sufficient to 
increase the incidence and severity of asthma. Temporal associations between tobacco smoke 
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exposures of fetuses/young children and subsequent altered lung responses have been 
investigated.  The association between smoke exposure and subsequent decreases in forced 
expiratory volume (a measure of lung function) was stronger when exposure was prenatal 
(Cunningham et al. 1994).  The asthma risk for children exposed in utero via maternal smoking 
was >2X that for children receiving postnatal ETS exposure (Cunningham et al. 1996). 
A 2001 review of the literature concluded “…that both in utero and, to some degree, 
passive (environmental) tobacco smoke (ETS) exposure adversely affect pulmonary function, 
and predispose to asthma symptoms” (Lodrup Carlsen and Carlsen 2001).  A questionnaire-
based survey of parents of 4000+ children revealed that in utero exposure to maternal smoking 
was a strong risk factor for wheezing and physician-diagnosed asthma in young children 
(Lannero et al. 2006). Neonates of non-smoking mothers exposed to ETS during pregnancy had 
higher serum levels of cotinine, (a major nicotine metabolite) than their mothers (Perera et al. 
2004).  This tendency to bioaccumulate smoke components could cause in utero ETS-exposed 
children to be particularly susceptible to respiratory problems.  
Rodent studies have confirmed that responses to ETS exposure in utero can be critical to 
subsequent respiratory and immune system responses.  Rats exposed to sidestream smoke for the 
first 100 days of life displayed no altered lung function or reactivity to methacholine (Joad et al. 
1993).  In contrast, female rats exposed continually to sidestream smoke in utero from day 3 of 
their gestation through week 10 after their birth, demonstrated a 24% decrease in lung dynamic 
compliance and a 20X increase in methacholine reactivity compared with rats exposed to smoke 
only during gestation or only after birth (Joad et al. 1995).  The timing effect was further refined 
when rats were exposed to filtered air or sidestream smoke (1mg/m
3
) in utero from day 3 of 
gestation through day 21 after their birth (Joad et al. 1999).  At 8 weeks of age, they displayed 
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significant increases in AHR and pulmonary artery pressure and decreases in dynamic 
compliance compared to controls.   
A recent report associated increased tumor incidence and growth with in utero exposures 
to mainstream smoke (Ng et al. 2006).  Offspring of B6C3F1 mice exposed in utero to smoke 
from gestational day 4 to birth, were injected with lymphoma cells at 5 and 10 weeks of age.  
Males exhibited a >2X increase in tumor incidence and more rapid tumor growth relative to 
controls.  This was accompanied by decreased cytotoxic T-lymphocyte activity without changes 
in natural killer cell activity, cytokine levels, lymphoid organ histology, or immune cell 
subpopulations.  
The conclusions of our study answer the questions posed in determining the effect of ETS 
exposure in utero on constitutive lung structure and function as well as its impact on the 
establishment of sensitivity or tolerance to an aeroallergen.  These conclusions also further 
implicate exposure to ETS in utero with altered AHR and immune responses to aeroallergen in 
juvenile and adult offspring, as previously reported both in human epidemiology and in rodent 
experimental literature. 
CONCLUSION 
 Four main conclusions emerge from this investigation.  
First, ETS exposure in utero alone does not alter respiratory structure or function in 
healthy mice.    
Second, ETS exposure in utero exacerbates initial adult responses to allergen as 
demonstrated by the EO vs. AO responses at 10 weeks (AHR) and the entire range of ESO vs. 
ASO responses at 15 weeks.  This effect is independent of whether OVA first is encountered as a 
tolerizing aerosol (EO at 10 weeks) or as part of a sensitization and challenge protocol (ESO at 
15 weeks).  
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Third, in this mouse model of asthma, increased AHR upon initial allergen exposure is 
not necessarily coupled with changes in histopathology, cytokine profile, or antibody levels 
(compare responses after OVA exposure at 10 vs. 15 weeks) but is related to in utero ETS 
exposure.  AHR is sometimes the only significant finding.  Coincidentally, in human asthmatic 
episodes, AHR is the preliminary clinical response and often the only initial finding. 
Fourth, OVA tolerance is not overcome by ETS exposure in utero. 
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CHAPTER 3 
 
ENVIRONMENTAL TOBACCO SMOKE EXPOSURE IN UTERO ALTERS GENE 
EXPRESSION IN LUNGS OF ADULT BALB/c MICE
2 
 
 
 
INTRODUCTION 
 
The incidence of asthma and allergy has increased dramatically during the past thirty 
years, primarily in industrialized countries (Eder et al. 2006).  Although improved availability 
and quality of medical care account for some of this increase, the magnitude of the increase 
surpasses the rate of improvement in healthcare delivery within these countries.  Furthermore, 
the rate at which this increase has occurred exceeds the generational time of these countries, 
thereby eliminating a strictly genetic etiology.  As a result, environmental exposures have 
become the focus of research on the rising incidence of asthma and allergy as well as many other 
complex diseases.  The National Institute of Environmental Health Sciences spearheads 
programs specifically to define and measure environmental exposures critical in human disease.  
The new Exposure Biology Program within the Genes and Environment Initiative of the National 
Institutes of Health targets gene and environmental exposure interactions resulting in human 
disease. 
  Development of complex diseases or disorders, including asthma, allergy, 
atherosclerosis, diabetes and obesity, has been linked to multiple genes or quantitative trait loci 
within mammalian genomes (Casas et al. 2006; Shah et al. 2006).  Multi-gene interactions are 
now suspected in most complex diseases (Chan et al. 2006; Motsinger et al. 2007; Yang et al. 
2005).  Increasingly, gene-environment interactions also are being examined for a role in the 
etiology of complex diseases (Colilla et al. 2003; Criswell et al. 2006; van Dellen et al. 2005; 
                                                 
2
 This chapter was published (non-copyright) in Environmental Health Perspectives 115(12): 1757-1766. 
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Williams et al. 2006).  Through generalized fetal stress or specific biochemical reactions, 
environmental exposures in utero appear to mediate complex chronic diseases (cardiovascular 
disease, obesity, diabetes, and asthma) having recognized genetic components (Genuis 2006; 
Martinez 2007; Okubo and Hogan 2004). Recent findings implicate environmental exposures in 
utero in developmental disorders like autism (Ashwood et al. 2006).  Although mild to moderate 
environmental exposures may not alter basic genetic information (DNA sequence), these 
exposures can determine the expression or repression of essential genes at developmentally 
critical points (Dolinoy et al. 2007; Li et al. 2003), thus contributing to chronic disease.  
 Altered lung function, increased asthma risk, and persistent lung function deficits in 
children (Gilliland et al. 2000; Gilliland et al. 2001; Li et al. 2000) have been associated with 
maternal smoking during pregnancy (in utero exposure).  Environmental tobacco smoke (ETS) 
aggravates childhood asthmatic responses (Gilliland et al. 2000; Lindfors et al. 1999; Mannino et 
al. 2001), and promotes premature adult cardiovascular disease in mice exposed to ETS in utero 
(Yang et al. 2004).  Altered lung function, exacerbation of symptoms, and acceleration of the 
disease processes seen with smoke exposure might arise from direct injury suffered by a 
developing fetus, by alteration of fetal gene expression, or through a combination of fetal injury 
and protective alteration of gene expression.  Fetal sensitivity to ETS may be heightened or ETS 
components may be bio-accumulated, as demonstrated by higher cotinine levels in neonates 
compared to their non-smoking mothers who had received ETS exposure during pregnancy 
(Perera et al. 2004). 
Ovalbumin (OVA) is an allergen commonly used in rodent models of allergic asthma. 
OVA-sensitization by i.p. injection followed by inhalation challenge with OVA aerosol elicits 
expansion of the T helper-2 (Th2) lymphocyte population.  Production of Th2 cytokines follows, 
leading to airway hyperresponsiveness (AHR) and inflammation characterized by eosinophilia 
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and appearance of OVA-specific immunoglobulin (Ig) E  (Zhang et al. 1997).  This sensitization 
and challenge protocol does not mimic the typical human experience of aerosol-only 
sensitization and challenge (Bice et al. 2000).  However, aerosol-only OVA exposure of mice 
results in little or no OVA-specific serum IgE, and no eosinophilic inflammatory response.  
Within this context, we designed experiments (Figure 2.1) to simulate the respiratory 
consequences to offspring of daily gestational exposures to ETS or filtered air (Penn et al. 2007).  
We combined daily ETS exposure in utero with post-natal OVA inhalation to test the hypothesis 
that ETS exposure in utero alters airway function and immune responses in adults.  At 10 weeks 
of age, in utero ETS and in utero air mice received aerosol OVA exposures.  The mice exposed 
to ETS in utero displayed significantly increased AHR without significant changes in 
histopathology, cytokine profiles or antibody levels.  At 15 weeks of age following OVA 
sensitization and challenge, mice exposed to ETS in utero, but not mice previously exposed to 
OVA, exhibited significantly increased AHR compared to in utero air controls.  ETS mice 
previously exposed to OVA demonstrated decreased numbers of bronchoalveolar lavage (BAL) 
eosinophils and PMN‟s, diminished AHR, and lower levels of IL-4, TNFα, and IFNγ compared 
to air controls. 
In the present study, we extracted mRNA from lungs of adult mice and examined differential 
gene expression profiles from four treatment groups (ESO, ASO, EOO, AOO; Figure 3.1). Lung 
samples for mRNA extraction were taken concomitantly with lung samples for histopathology, 
clinical pathology, and immunology assays (Penn et al. 2007).  No gender differences were 
detected in immune responses, lung function or histopathology of offspring in that study.  
Nevertheless, RNA for individual microarray analyses in  this  study  was  examined  from 
females only (4 females/treatment group) to eliminate any unrecognized gender effects. We used 
PCR to further examine selected asthma-related and inflammatory genes in these subsets of each 
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treatment group and to determine whether the differential gene expression levels were consistent 
with the pathophysiology and the immune system responses that we previously reported (Penn et 
al. 2007). 
 
 
Figure 3.1:  
a
days 1-19 of gestation; 
b
weeks = age of offspring; 
c
Treatment group 
designation based on gestational, 8 week, and 11-14 week exposures; 
d
tolerize=OVA 
tolerization established through inhalation of 1% OVA aerosol (in saline), 20 minutes daily 
for 10 days;
  e
sens/chal = OVA sensitization was established by (i.p.) injections (80 µg OVA 
in 2.0 mg alum), one each at 11 and 13 weeks.  Three 20-minute inhalation exposures to 1% 
OVA in saline, every other day at 14 weeks plus an additional 20-minute exposure one day 
before sacrifice at 15 weeks constituted OVA challenge; 
f
AIR = HEPA-filtered air.  
 
MATERIALS AND METHODS  
Animal Protocols 
  
Eight-week old BALB/c mice (Harlan, Indianapolis, IN), were housed and handled 
according to the Guide for the Care and Use of Laboratory Animals (Institute of Laboratory 
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Animal Resources. 1996. Washington D. C., National Academy Press).  The Louisiana State 
University Institutional Animal Care and Use Committee approved all animal procedures.  All 
animals were handled humanely and care was taken to assure alleviation of pain and suffering.  
A barbiturate solution (Beuthanasia-D, Schering-Plough, Kenilworth, NJ) was used via 
intraperitoneal injection (0.2 ml per mouse) for all sacrifices. 
Exposures   
 
Pre- and post-natal exposure protocols have been described in detail (Penn et al. 2007).  
Briefly, pregnant mice were exposed in dynamic exposure chambers to either ETS mixed with 
HEPA-filtered air (final total suspended particle concentration =10mg/m
3
;
 
carbon monoxide 
concentration 44.5 ppm) or to HEPA-filtered air 5 hours per day for days 1-19 of gestation.  Half 
of the mice from each of these groups inhaled 1% OVA aerosol (20 min/day; 10 days; 7-8 weeks 
of age) to produce tolerance, while the other half inhaled saline aerosol.  All mice were OVA-
sensitized and challenged (Figure 3.1), then sacrificed one day following a final OVA challenge 
at 15 weeks of age to determine the effects of ETS exposure in utero on responses to OVA 
sensitization/challenge in mice not previously exposed to OVA (ESO, ASO) and on OVA 
tolerance in mice previously exposed to OVA (EOO, AOO).   No offspring were exposed to ETS 
after birth.   
Lung Harvest and mRNA Extraction 
 
 Left lung lobes were excised, placed in RNAlater (Ambion, Austin, TX), and stored at -
80°C.  Subsequently, these samples were transferred to 1mL TRIzol (Invitrogen, Carlsbad, CA) 
and homogenized with a Mixer Mill MM 300 (Qiagen, Valencia, CA) with a copper bead.  
Chloroform was added to the homogenate, mixed by inversion, and centrifuged @ 4°C to 
separate phases.  The RNA-containing aqueous phase was transferred to an RNeasy Micro Kit 
(Qiagen, Valencia, CA).  The manufacturer‟s protocol was followed, omitting Buffer RLT.  
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Remaining DNA was eliminated using a column RNase-Free DNase Set (Qiagen, Valencia, CA).  
An additional Buffer RPE wash was used to remove residual salts followed by an additional 2 
minute spin to evaporate residual ethanol. 
 RNA samples were checked for quantity and purity with a NanoDrop ND-1000 
Spectrophotometer (NanoDrop, Wilmington, DE).  Values generated from the NanoDrop for all 
samples fell into the following ranges, 260/280 ratio: 2.09-2.17, 260/230 ratio: 2.20-2.27, 
concentration: 1200-1900 ng/uL.  Further quality assays were performed on 1:5 dilutions of 
RNA samples with an Agilent 2100 BioAnalyzer (Agilent Technologies, Palo Alto, CA) and 
Agilent RNA 6000 Nano Series II Kits.  All samples fell into the following ranges, 28S/18S 
ratio: 1.3-1.8, RNA Integrity Number: 8.5-9.6. 
Microarray Assay 
 
 Global gene expression in the lung was assessed in individual mice (4 female 
mice/treatment group) on Affymetrix Mouse Genome 430 2.0 Arrays representing more than 
39,000 transcripts with over 45,000 probe sets.  The arrays were processed at the Research Core 
Facility of Louisiana State University Health Science Center-Shreveport.  
Double stranded cDNA synthesized from total RNA was used to create cRNA, which 
was then biotinylated, fragmented, and added to a hybridization cocktail that included probe 
array controls, bovine serum albumin, and herring sperm DNA.  This cocktail was then 
hybridized (16 hours; 45°C) to oligonucleotide probes on a GeneChip Mouse 430 2.0 Array in a 
GeneChip Hybridization Oven 640.  Immediately following hybridization, the array underwent 
an automated washing and staining protocol on a GeneChip Fluidics Station and was scanned 
with a GeneChip Scanner 3000.  Data collection and processing of initial raw data were 
performed by a GeneChip Workstation.  All gene chips and instrumentation were from 
Affymetrix (Santa Clara, CA). 
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Gene Expression Analysis  
 
 GeneChip Workstation data were sent to Expression Analysis Systems (Durham, NC).  
Initially, a principal component analysis was used to determine clustering of experimental units.  
The analysis revealed clustering by treatment group with greater variation between groups than 
within groups (data not presented), thus validating subsequent comparisons between treatment 
groups.  Prior to making these comparisons, data were subjected to reduction of invariant probes 
(REDI) to remove previously determined mal-performing probes from the data set.  Pairs of 
treatment group data underwent permutation analysis for differential expression (PADE),
 
that 
accounts for false positives by tabulating a false discovery rate (FDR) based on a permutation-
generated reference curve (technical information on REDI and PADE analyses available at 
www.expressionanalysis.com).  Following REDI and PADE, expression data were tabulated for 
each remaining transcript, including individual transcript p-value, FDR, fold change, Affymetrix 
probe ID, gene symbol, and functional summary.  For inclusion in the analysis transcripts had to 
be present in every sample.  All transcripts included in this study had a fold change of at least 1.5 
(up or down), and both an individual p-value and FDR <0.05 
Pathway Analyses  
 
 Gene expression data were analyzed with the network- and pathway-building software, 
Ingenuity Pathways Analysis 4.0; gene networks and canonical pathways were examined using 
the Ingenuity Analysis Knowledge Database (Ingenuity Systems, Redwood City, CA).  Identified 
networks and pathways were scrutinized for phenotypic relevance.  Select genes were identified 
from the literature for confirmation by quantitative real-time PCR analysis.  Custom networks 
were created to demonstrate the connections between the genes identified in our expression 
analyses.  
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Quantitative Real Time PCR (qRT-PCR) 
 
 Cytokine changes that were apparent at the protein level (IL-4, IL-5, IL-10, IL-13, TNFα; 
Penn et al. 2007) were not seen in the filtered microarray data.  In addition, several asthma-
related genes did not pass all of the filtering criteria and consequently were not identified in the 
filtered data as being differentially expressed, although preliminary data suggested otherwise.  
To clarify the status of these genes, the same fifteen-week female mouse RNA samples that had 
been subjected to the microarray assay underwent qRT-PCR to determine differential expression 
of 14 genes previously associated with asthma by other investigators (Arg1, Ccl8, Ccl11, Ccl24, 
Ear11, Mcpt1, Sprr2a, Chi3l3, Chi3l4, Chia, Pde4b, Pde4d, Slc7a2, Tgfb1), as well as 7 
cytokine genes associated with asthma and/or pulmonary inflammation (Ifnγ, Il1b, Il4, Il6, Il10, 
Il13, Tnfa).  The results of the 4 individuals in each treatment group were averaged, as they were 
with microarray analysis, to arrive at a fold change value for the treatment group. 
 RNA from each sample was converted to cDNA with the High Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems, Foster City, CA).  Real-time PCR was performed on 
cDNA with a Model 7300 Real-Time PCR System with TaqMan Universal PCR Master Mix and 
TaqMan Gene Expression Assays (Applied Biosystems) for the selected genes.  All data 
collected and analyzed here adhere to the guidelines for Minimal Information About a 
Microarray Experiment (MIAME). 
RESULTS  
An ETS trend detected in pathophysiological data (Penn et al. 2007)  is supported here by 
differential gene expression in ESO versus ASO mice.  Following REDI and PADE analyses, 80 
transcripts in our study met all filtering criteria (fold change ≥ 1.5, FDR < 0.05, transcript p- 
value < 0.05).  After removal of duplicate, unmapped, and poorly characterized transcripts, 60 
unique transcripts (51 down- and 9 up-regulated) remained that were differentially expressed in 
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the lungs of ESO versus ASO mice (Table 3.1).  The actual limits of filtering criteria for these 
genes were: fold change 3.25 to 1.67 and -3.37 to -1.58, FDR < 0.04, transcript p-value < 0.005.  
None of the asthma-related genes that we targeted for qRT-PCR analysis (Table 3.2) were 
differentially expressed according to filtered microarray data in ESO versus ASO mice.   
 
Table 3.1:  ETS Exposure In Utero Changes Expression Levels of Genes in the Lungs of 
OVA Sensitized Mice 
Affymetrix 
ID 
Fold 
Change FDR p-value 
Gene 
Symbol Function Process 
1448303_at 3.25 0.040 0.0018 Gpnmb Integrin binding Inhibit proliferation 
1441557_at 2.12 0.040 0.0008 Setd8 Histone (H4) methylation Control cytokinesis 
1424706_at 2.02 0.037 0.0003 Zfp51 DNA/protein binding Unknown 
1444396_at 2.01 0.040 0.0008 Trp53inp2 Unknown Unknown 
1424704_at 1.98 0.037 0.0002 Runx2 Transcription inhibitor Inhibit proliferation 
1421525_a_at 1.92 0.037 0.0002 Birc1e Unknown Macrophage activation/death 
1450541_at 1.89 0.037 0.0003 Pvt1 Unknown Unknown 
1453281_at 1.88 0.040 0.0006 Pik3cd VEGFactivation Promote immune responses 
1434500_at 1.67 0.037 <.0001 Ttyh2 Chloride channel Chloride channel regulation 
1456868_at -3.37 <.001 0.0004 Mrcl3 Cytoskeleton actin binding Motility, elasticity, and apoptosis 
1457610_at -2.91 <.001 0.0006 Rbck1 Zinc and protein binding Ubiquitinization 
1433774_x_at -2.81 <.001 0.0006 Cog1 Protein binding Golgi transport 
1441840_x_at -2.78 <.001 0.0001 Kiaa0963 Unknown Unknown 
1447530_at -2.77 <.001 0.0012 F8a Endosomal binding/motility Endosomal formation/function 
1440180_x_at -2.76 <.001 <.0001 Zbtb3 Dna/protein binding Unknown 
1458354_x_at -2.62 <.001 0.0006 Krt28 Unknown Unknown 
1443829_x_at -2.55 <.001 0.0001 Coasy Adenylyltransferase Coenzyme A regulation 
1455853_x_at -2.43 <.001 0.0009 Tspan31 Transmembrane protein Proliferation, differentiation, growth 
1449804_at -2.36 0.040 0.0036 Pnmt Tyrosine metabolism Growth 
1458325_x_at -2.34 0.040 0.0043 Bmf Cytoskeleton myocin binding Cell repair/ induce apoptosis 
1436149_at -2.23 0.037 0.0020 Cox5b Cytochrome C subunit Oxidative phosphorylation 
1427527_a_at -2.20 <.001 0.0001 Pthlh Calcium binding Proliferation, differentiation, growth 
1443752_at -2.17 <.001 0.0009 Kiaa1529 Unknown Unknown 
1438638_x_at -2.17 0.037 0.0020 Fam116b Unknown Unknown 
1459766_x_at -2.14 <.001 0.0004 Sf1 Activate transcription Proliferation, differentiation, growth 
1421788_x_at -2.13 <.001 0.0011 Klk13 Unknown Unknown 
1421621_at -2.10 <.001 0.0003 Rasgrf2 Guanyl nucleotide exchange Growth and signaling 
1452538_at -2.08 <.001 0.0006 Igh-V3609N
b 
Antigen binding Proliferation, differentiation, growth 
1456746_a_at -2.08 <.001 0.0005 Cd99l2 Unknown Unknown 
1441935_at -2.07 <.001 0.0002 Ankra2 Activate transcription Proliferation, differentiation, growth 
1419216_at -2.04 0.040 0.0032 Azi1 Unknown Unknown 
1426325_at -2.02 0.037 0.0015 Kif1c Cytoskeleton binding protein Motility and Golgi transport 
1424845_a_at -1.94 0.037 0.0011 Cep68 Unknown Unknown 
1449218_at -1.91 0.037 0.0019 Cox8b Cytochrome assembly Oxidative phosphorylation 
1425155_x_at -1.88 0.037 0.0017 Csf1 Activate transcription Proliferation, differentiation, growth 
1433792_at -1.87 0.040 0.0026 Nrip2 Inhibit transcription Unknown 
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Genes differentially expressed by microarray in OVA-sensitized mice exposed in utero to ETS 
or AIR (ESO vs. ASO)
a
; 
a 
Mice were exposed in utero to ETS or AIR, then OVA-sensitized by 
i.p. injections and challenged with aerosol OVA as described in Material and Methods; 
b
Human homologue IGH-1A. 
 
 
 
However, when examined by qRT-PCR, four asthma-related genes were identified as up-
regulated (Arg1, Ccl24, Slc7a2, Mcpt1).   In each case, the fold change from the microarray 
analysis was very similar to that determined by qRT-PCR (Table 3.2).  Neither microarray 
analysis nor qRT-PCR revealed differential expression of cytokine genes in ESO versus ASO 
mice (Table 3.3). 
A significant ETS effect demonstrated pathophysiologically (Penn et al. 2007) is 
supported here by differential gene expression in EOO versus AOO mice.  Following REDI and 
PADE analyses, 85 transcripts were initially identified.   Filtering criteria for these transcripts  
(Table 3.1 continued) 
 
1439745_at -1.84 0.037 0.0010 Cacng7 Calcium channel Calcium channel regulation 
1425120_x_at -1.83 0.040 0.0019 Fam14a Unknown Unknown 
1454634_at -1.83 0.037 0.0014 Fuk Glycoprotein phosphorylation Leukocyte trafficking 
1419387_s_at -1.83 <.001 0.0005 Muc13 Transmembrane protein Unknown 
1440368_at -1.83 0.040 0.0023 Jmjd2b Unknown Unknown 
1459977_x_at -1.81 0.037 0.0011 Cox10 Heme synthesis Oxidative phosphorylation 
1450704_at -1.81 0.037 0.0010 Ihh Transferase Proliferation, differentiation, growth 
1416518_at -1.77 0.040 0.0019 H1foo DNA and chromatin binding Chromatin folding 
1417305_at -1.77 0.040 0.0019 Des Cytoskeleton binding protein  Smooth Muscle motility/elasticity 
1435015_at -1.75 <.001 0.0005 Zfp787 DNA/protein binding Unknown 
1426274_at -1.74 <.001 0.0001 Slc9a8 Sodium/hydrogen exchange Unknown 
1439144_at -1.74 <.001 0.0001 Cwf19l1 Unknown Cell cycle control 
1430236_s_at -1.74 <.001 0.0001 Gdsm2 Unknown Unknown 
1450538_s_at -1.72 <.001 0.0003  Mcpt9  Peptide catabolism Mast cell degranulation 
1448927_at -1.70 0.040 0.0012 Kcnn2 Potassium channel Potassium channel regulation 
1427409_at -1.68 0.037 0.0010 9-Mar Unknown Unknown 
1436083_at -1.67 0.037 0.0009 Lrp3 Lipoprotein binding Adhesion, apoptosis 
1434463_at -1.65 0.037 0.0009 Bfsp2 Cytoskeleton component Motility, elasticity, and structure 
1459073_x_at -1.63 0.040 0.0011 Fgf14 Ion channel protein binding Sodium channel regulation 
1421975_a_at -1.63 0.040 0.0015 Add2 Cytoskeleton actin binding Motility, elasticity, and structure 
1421329_a_at -1.61 0.037 0.0004 Smyd1 Inhibit transcription Chromatin remodeling 
1426493_a_at -1.61 <.001 0.0001 Kifc2 Cytoskeleton binding protein Motility and Golgi transport 
1432883_at -1.59 0.037 0.0006 Wdr87 Unknown Unknown 
1420569_at -1.58 <.001 <.0001 Chad   Unknown Chrondrocyte adhesion 
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Table 3.2: Microarray and qRT-PCR Evaluations of Differential (fold-change) Expression 
of Asthma-Related Genes Yield Similar Results 
  Arg1 Ccl8 Ccl11 Ccl24 Ear11 Mcpt1 Sprr2a 
  PCR 
Gene 
Chip 
PCR 
Gene 
Chip 
PCR 
Gene 
Chip 
PCR 
Gene 
Chip 
PCR 
Gene 
Chip 
PCR 
Gene 
Chip 
PCR 
Gene 
Chip 
AOO v ASO -5.8 -6.3d -2.9 -1.8 -3.6 -3.8a -4.7 -2.6d -5.0 -4.6a -2.0 -1.3d -17.3 -5.6d 
ESO v ASO 2.4 2.2d 1.0 -1.1d 1.2 1.3d 2.1 1.8d 1.4 1.3d 1.7 1.2d -1.0   1.1d 
EOO v ESO -26.8 -22.0 -8.2 -5.2 -7.7 -7.0 -17.0 -5.2d -41.3 -23.8 -11.2 -1.5 -131.4        -7.3c 
EOO v AOO -1.9 -1.6d -2.8 -3.2 -1.7 -1.5d -1.8 -1.1d -5.7 -4.1d -3.2 1.0d -7.9 -1.4e 
                              
  Chi3l3 Chi3l4 Chia Pde4b Pde4d Slc7a2 Tgfβ1 
  PCR 
Gene 
Chip 
PCR 
Gene 
Chip 
PCR 
Gene 
Chip 
PCR 
Gene 
Chip 
PCR 
Gene 
Chip 
PCR 
Gene 
Chip 
PCR 
Gene 
Chip 
AOO v ASO -3.6 -1.5e 
-
18.5 
-12.6 -3.9 -2.2d 1.3 1.6a 1.1 1.1e -1.6 -1.3e -1.1 -1.1d 
ESO v ASO 1.2 1.1e -1.1 -1.0d 1.2 1.2d 1.1 -1.1e 1.0 1.1e 1.7 1.7a 1.2 -1.1d 
EOO v ESO -17.6 -3.6b 
-
228.5 
-45.7 -8.3 -4.3 1.0 4.8 1.1 1.1e -4.0 -1.6a -1.8 -1.6d 
EOO v AOO -4.1 -2.1b 
-
13.6 
-3.7d -1.8 -1.6d -1.1 -1.1e 1.1 1.1e -1.5 -1.2e -1.4 -1.3d 
 
 
were:  fold-change 2.13 to 1.50 and -3.24 to -1.50, FDR ≤ 0.041, transcript p-value < 0.005.  
Removal of duplicate, unmapped, and poorly characterized transcripts left 31 down-regulated 
and 41 up-regulated transcripts differentially expressed in EOO mice relative to AOO controls 
(Table 3.4).  Among the down-regulated genes, one asthma-related gene (Ccl8) met the filtering 
criteria.  qRT-PCR analysis verified results for Ccl8 and indicated a down- regulation of 10 other 
asthma-related genes (Arg1, Ccl11, Ccl24, Ear11, Mcpt1, Sprr2a, Chi3l3, Chi3l4, Chia, Slc7a2) 
a did not pass FDR 
b average of two transcripts 
c average of two transcripts, one did not pass FDR 
d did not pass transcript p-value or FDR 
e average of two transcripts, did not pass transcript p-value or FDR 
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in EOO versus AOO mice (Table 3.2).    Evaluation by qRT-PCR demonstrated down-regulation 
of 6 cytokine genes in EOO mice relative to AOO mice (Il4, Il6, Il10, Il13, Tnfa, Il1b; Table 
3.3).  Again, differential expression of these cytokines was not detected by microarray.  Gene 
expression comparisons of ASO versus AOO or ESO versus EOO mice, reveal that differences 
exist primarily as a result of airway inflammation present in mice not previously exposed to 
OVA (ASO and ESO) and absent in mice previously exposed to OVA (AOO and EOO).  AOO 
mice had 673 down- and 1037 up-regulated transcripts relative to ASO mice, while EOO mice 
had 847 down- and 1465 up-regulated transcripts relative to ESO mice (data available upon 
request).  In each of these cases, unidentified, duplicate, and unmapped transcripts accounted for 
15-25% of the total transcripts.  
 
Table 3.3:  Differential (fold-change) Expression of Cytokine Genes:  Microarray vs. qRT-
PCR 
  
 
 
 
  
Ifnγ Il1b Il4 Il6 Il10 Il13 Tnfα 
  
PCR 
Gene 
Chip 
PCR 
Gene 
Chip 
PCR 
Gene 
Chip 
PCR 
Gene 
Chip 
PCR 
Gene 
Chip 
PCR 
Gene 
Chip 
PCR 
Gene 
Chip 
AOO v 
ASO 
-1.1 -1.1d -1.1 -1.1d -2.1 -1.2e -1.6 -1.0d -1.7 -1.1d -4.9 -1.4e -1.2 -1.1d 
 ESO v 
ASO 
1.1 -1.0d -1.1 -1.4d 1.3 1.3d -1.3 -1.1d -1.2 -1.1d -1.1 -1.3d 1.0 -1.1d 
 EOO v 
ESO 
-1.6 -1.0d -1.6 -1.3d -4.7 -1.7a -2.2 -1.0d -4.8 -1.2d -17.2 -1.1d -2.1 -1.2d 
EOO v 
AOO 
-1.3 -1.0d -1.6 -1.6d -1.8 -1.1d -1.9 -1.0d -3.2 -1.0d -3.8 -1.0d -1.8 -1.1d 
a did not pass FDR 
b average of two transcripts 
c average of two transcripts, one did not pass FDR 
d did not pass transcript p-value or FDR 
e average of two transcripts, did not pass transcript p-value or FDR 
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Table 3.4:  In Utero ETS Exposure Changes Expression Levels of Genes in the Lungs of 
OVA Tolerant Mice Subsequently Challenged with OVA 
Affymetrix 
ID 
Fold 
change FDR p-value 
Gene 
Symbol Function Process 
1425206_a_at 2.13 <.001 0.0002 Ube3a Ubiquitin conjugation Protein catabolism 
1415854_at 1.94 <.001 0.0006 Kitlg Erk, Mapk, Akt activation Proliferation signaling  
1417188_s_at 1.94 <.001 0.0009 Hip2 Activate transcription Ubiquitin regulation 
1449217_at 1.87 0.041 0.0028 Casp8ap2 NFκB activation Apoptosis/survival signaling 
1450924_at 1.83 <.001 0.0005 Hdgfrp3 Bind growth factor Regulation of growth factor 
1422975_at 1.8 <.001 <.0001 Mme Degrade bradykinin/elastin Extracellular matrix repair 
1428025_s_at 1.8 <.001 0.0004 Pitpnc1 Phosphatidylinositol binding Phosphatidylinositol regulation 
1436917_s_at 1.76 0.041 0.0031 Gpsm1 Activate GTPases Regulate G-protein receptor activity 
1421230_a_at 1.74 0.041 0.0033 Msi2h Unknown Unknown 
1418489_a_at 1.73 <.001 0.0001 Calcrl Mobilize calcium/cAMP Control smooth muscle migration 
1451866_a_at 1.73 <.001 0.0003 Hgf Erk, Mapk activation Suppress dendritic cell activation 
1453139_at 1.72 <.001 0.0002 Nudt12 Hydrolase Nucleotide regulation 
1425845_a_at 1.68 0.041 0.0012 Shoc2 Co-inhibitor of Raf1 Regulate Ras pathway 
1447926_at 1.67 0.041 0.002 Arl5 Unknown Unknown 
1417069_a_at 1.67 0.041 0.0015 Gmfb NFκB activation Apoptosis/survival signaling 
1448665_at 1.67 0.041 0.0015 Dmd Actin binding Cytoskeletal anchoring 
1451146_at 1.66 0.041 0.0016 Zfp386 Chromatin/DNA binding Unknown 
1449888_at 1.66 0.041 0.0016 Epas1 Activate Vegf Control vascular remodeling 
1418231_at 1.64 0.041 0.0011 Lims1 Pi3k, Akt activation Integrin signaling 
1420514_at 1.64 0.041 0.0016 Tmem47 Unknown Unknown 
1437784_at 1.63 <.001 0.0002 Runx1t1 Increase Myc, Jun expression Proliferation/growth 
1437668_at 1.63 0.041 0.0014 Ccrl1 Activate cytokines Immune signaling 
1426517_at 1.61 <.001 0.0002 Gnaz GTP/Erk, Mapk activation Differentiation signaling 
1447944_at 1.61 <.001 0.0001 Zkscan1 Unknown Unknown 
1425370_a_at 1.6 0.041 0.0021 Erg Increase Tgfb2 expression Inhibit apoptosis 
1451827_a_at 1.6 0.041 0.0011 Nox4 NADPH Oxidase ROS metabolism/inhibit proliferation 
1428345_at 1.58 0.041 0.0018 Ppapdc2 Diphosphate phosphotase Inhibit PMN-mediated inflammation 
1429776_a_at 1.57 0.041 0.0022 Dnajb6 Co-chaperone(hsp70) Protein transport and folding 
1419805_s_at 1.57 0.041 0.0021 Ggps1 Prenyltransferase Sterol synthesis 
1437302_at 1.56 0.041 0.001 Adrb2 Erk, Mapk activation Motility/adhesion signaling 
1418780_at 1.55 <.001 0.0001 Cyp39a1 Hydroxylase Lipid metabolism 
1437982_x_at 1.54 0.041 0.0015 Cox15 Cytochrome c assembly Oxidative phosphorylation 
1438530_at 1.54 <.001 0.0002 Tfpi Inhibition of F10 Coagulation regulation 
1416701_at 1.53 0.041 0.0016 Rnd3 GTP-linked protein binding Inhibit smooth muscle contraction 
1452328_s_at 1.53 0.041 0.0018 Pja2 Ubiquitin conjugation Ubiquitin regulation 
1418429_at 1.53 0.041 0.0013 Kif5b Increase microtubule mobility Cell mobility 
1429434_at 1.52 0.041 0.0015 Pik3ca Erk, Mapk, Akt, Rho activation Proliferation signaling 
1459973_x_at 1.51 <.001 0.0001 Dpp4 Cytokine proteolysis Inhibit Tcell activation 
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Genes differentially expressed by microarray in OVA-tolerant mice exposed in utero to ETS or 
AIR (EOO vs. AOO)
a
; 
a 
Mice were exposed in utero to ETS or AIR, then exposed to OVA-
aerosol at 7 to 8 weeks of age then OVA-sensitized by i.p. injections and challenged with 
aerosol OVA at 15 weeks of age as described in Material and Methods; 
b
Human homologue 
IGH-1A. 
(Table 3.4 continued) 
 
1453908_at 1.51 0.041 0.0011 Ptprb Sodium channel regulation Proliferation signaling 
1452385_at 1.51 <.001 <.0001 Usp53 Ubiquitin-specific peptidase Ubiquitin regulation 
1420019_at 1.5 0.041 0.0015 Tm4sf3b Integrin binding Activation/growth signaling 
1448872_at -3.24 0.041 0.003 Reg3g Unknown Epithelial cell regeneration 
1419684_at -3.19 0.041 0.0042 Ccl8 Activate WBC cytokines Immune cell activation 
1418930_at -2.99 0.041 0.0037 Cxcl10 Mast cell/monocyte chemotaxis Inflammatory response 
1438148_at -2.81 <.001 0.0009 Gm1960c Macrophage chemotaxis Inflammatory response 
1448377_at -2.63 <.001 0.0007 Slpi Bind peptidase/inhibit NFκB Inactivate leukocyte peptidase 
1449401_at -2.42 <.001 0.0009 C1qc Complement activation Blood cell activation 
1450849_at -2.26 0.041 0.0037 Hnrpu Tranport snRNA to cytoplasm RNA processing 
1419128_at -2.19 <.001 0.0008 Itgax Adhesion/signaling Immune response 
1421326_at -2.17 0.041 0.0016 Csf2rb1 Erk, Mapk, Akt activation Proliferation, differentiation, survival  
1440801_s_at -2.1 0.041 0.0022 Adrbk2 G-protein receptor activation Activate receptor signaling 
1416871_at -2.08 0.041 0.0025 Adam8 Metalloendopeptidase Release of IgE low affinity receptor 
1419699_at -2.02 0.041 0.0012 Scgb3a1 Akt inhibition Epithelial cell differentiation 
1447071_at -1.85 0.041 0.0025 Tcf7l2 Activate transcription Tcell extravasation 
1437864_at -1.83 <.001 0.0001 Adipor2 Activate Ampk Lipid metabolism 
1417025_at -1.8 0.041 0.001 H2-Eb1d MHC II antigen binding Antigen presentation 
1456022_at -1.78 0.041 0.0015 Hipk2 Increase Tgfβ, Jnk transcription Cell cycle progression signaling 
1425477_x_at -1.73 0.041 0.0008 H2-Ab1e MHC II antigen binding Antigen presentation 
1446050_at -1.71 <.001 0.0001 Magi1 ATP-dependent Akt activation Motility/adhesion signaling 
1425294_at -1.69 0.041 0.001 Slamf8 Unknown Immune response 
1450355_a_at -1.63 0.041 0.0009 Capg Caps actin filaments Leukocyte motility and phagocytosis 
1422725_at -1.63 0.041 0.0014 Mak cATP/nucleotide binding Cell differentiation signaling 
1415871_at -1.61 0.041 0.0004 Tgfbi Integrin binding Motility/adhesion signaling 
1419315_at -1.61 0.041 0.0006 Slamf9 Unknown Immune response 
1424758_s_at -1.59 0.041 0.0012 Serpina10 Inhibition of F10 Coagulation regulation 
1433963_a_at -1.56 0.041 0.0006 BC032204f Unknown Unknown 
1429475_at -1.56 0.041 0.0008 Sts1 Ubiquitin conjugation Suppress Tcell signaling/endocytosis 
1419721_at -1.55 0.041 0.0005 Gpr109b Inhibit cAMP Lipid metabolism 
1426324_at -1.54 0.041 0.0006 H2-D1g MHC I antigen binding Antigen presentation 
1425837_a_at -1.53 0.041 0.0009 Ccrn4l Activate RNA polymerase II Circadian rhythm 
1416985_at -1.51 <.001 <.0001 Sirpa Erk, Mapk, Akt inhibition Immune signaling 
1428942_at -1.5 0.041 0.0002 Mt2a NFκB activation Apoptosis/survival signaling 
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For ESO versus ASO and EOO versus AOO comparisons, genes were organized into 
networks and were identified within canonical pathways based on reference literature.  The 
analyses allowed identification of experimentally denoted genes within defined functional 
pathways and networks based upon previously identified gene-gene or protein-protein 
relationships.  Within the ESO-ASO comparison, 34 genes (8 up-regulated and 26 down-
regulated) had demonstrable network connections (Figure 3.2).  Among the down-regulated 
genes were nine involved in promoting proliferation/differentiation/growth (Tspan31, Pmnt, 
Pthlh, Sf1, Rasgrf2, Igh-V3609N, Ankra2, Csf1, Ihh) and four associated with increased 
ubiquitination/apoptosis (Mrcl3, Rbck1, Bmf, Lrp3).  Among the up-regulated genes were three 
associated with inhibition of proliferation (Gpnmb, Setd8, Runx2) and one promoting 
inflammatory and immune responses (Pik3cd), as well as four asthma-related genes (Arg1, 
Ccl24, Slc7a2, Mcpt1) identifiable only through qRT-PCR.  
Within the EOO-AOO comparison, 71 genes (43 down-regulated and 28 up-regulated) 
had documented network connections (Figure 3.3) including the 14 genes identified by qRT- 
PCR.  Of 43 down-regulated genes, 32 enhance immune and inflammatory responses or have 
been implicated in asthma pathogenesis, including six cytokine (Il1b, Il4, Il6, Il10, Il13, Tnfa), 
four chemokine (Ccl8, Ccl11, Ccl24, Cxcl10), and eight asthma-related genes (Arg1, Ear11, 
Mcpt1, Sprr2a, Chi3l3, Chi3l4, Chia, Slc7a2).  Among the up-regulated genes were six involved 
in positive regulation of proliferation/differentiation/growth (Kitlg, Runxlt1, Gnaz, Pik3ca, 
Ptprb, Tmrsf3), seven associated with increased ubiquitination/apoptosis (Ube3a, Hip2, 
Casp8ap2, Gmfb,  Erg,  Pja2,  Usp53),  and four  involved in suppression of immune  responses 
(Hgf, Ppapdc2, Rnd3, Dpp4).  The majority of genes with altered expression (up or down) play 
roles in the immune system.  The non-cytokine immune genes with in utero ETS-exposure 
mediated changes in expression are presented in Table 3.5. 
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Figure 3.2:  ETS Exposure in Utero Creates a Network of Altered Gene Expression in OVA 
Sensitized Mice.  Green represents down-regulation and red up-regulation (fold-changes ≥ 
1.5); white nodes represent fold-change < 1.5.  Intensity of color increases with increasing 
fold-change (numbers represent fold-change values).  Dotted lines indicate indirect 
relationships and solid lines direct interactions.  All gene symbols are human homologue 
designations.  Network constructed with Ingenuity Systems software. 
 
 
 
 
52 
 
 
  
 
 
 
Figure 3.3:  ETS Exposure in Utero Creates a Network of Altered Gene Expression in OVA 
Tolerant Mice Subsequently Challenged with OVA.  Green represents down-regulation 
and red up-regulation (fold-changes ≥ 1.5); white nodes represent fold-change < 1.5.  
Intensity of color increases with increasing fold-change (numbers represent fold-change 
values).  Dotted lines indicate indirect relationships and solid lines direct interactions.  All 
gene symbols are human homologue designations.  Network constructed with Ingenuity 
Systems software. 
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Table 3.5:  Gene Expression Changes Mediated by ETS Exposure In Utero Diminish 
Immune Responses in OVA Tolerant Mice Re-exposed to OVA 
 
Gene Process Influence Change Reference 
Hgf Dendritic cell antigen presentation inhibits up (Okunishi et al. 2005) 
Ppapdc2 PMN activation inhibits up (Fukunaga et al. 2006) 
Rnd3 Leukocyte migration inhibits up (Sanchez-Madrid and del Pozo 1999) 
Dpp4 Cytokine cleavage promotes up (Boonacker and Van Noorden 2003) 
H2-Ab1 Antigen presentation promotes down (Stevenson et al. 2000; Wolk et al. 2000) 
H2-Eb1 Antigen presentation promotes down (Stevenson et al. 2000; Wolk et al. 2000) 
H2-D1 Antigen presentation promotes down (Stevenson et al. 2000; Wolk et al. 2000) 
Ccl11 Pro-inflammatory signaling promotes down (Mantovani et al. 2004) 
Ccl24 Pro-inflammatory signaling promotes down (Mantovani et al. 2004) 
Ccl8 Pro-inflammatory signaling promotes down (Mantovani et al. 2004) 
Cxcl10 Pro-inflammatory signaling promotes down (Mantovani et al. 2004) 
Cxcl2 Pro-inflammatory signaling promotes down (Mantovani et al. 2004) 
Slamf8 Lymphocyte activation signaling promotes down (Graham et al. 2006) 
Slamf9 Lymphocyte activation signaling promotes down (Graham et al. 2006) 
Tcf7l2 T-cell maturation/development promotes down (Willinger et al. 2006) 
Slpi Control of Mast cell/PMN proteases promotes down (Wright et al. 1999) 
Sts1 T cell signaling modulation promotes down (Carpino 2004) 
Adam8 Soluble IgE release promotes down (Fourie et al. 2003) 
Igfbi Pro-inflammatory cytokine (IL6) production promotes down (Moller et al. 1994) 
Capg Macrophage mobility/phagocytosis promotes down (Parikh et al. 2003) 
Sirpa Modulates macrophage phagocytosis promotes down (van den Berg et al. 2004) 
Itgax Dendritic cell maturation promotes down (Hebel et al. 2006) 
C1qc Antigen recognition/uptake promotes down (Sontheimer et al. 2005) 
 
 
DISCUSSION 
 
This is the first report to identify gene expression changes in the adult lung following 
ETS exposure in utero.  In addition, the gene expression results presented here (microarray and 
RT-PCR) provide a molecular framework within which to consider the pathophysiological, lung 
function and inflammatory responses we recently reported (Penn et al. 2007).   
The ETS exposure level (TSP=10mg/mm
3
) used in this study is the same that was used in 
our other in utero (Yang et al. 2004) and earlier adult exposure studies (Bowles et al., 2005; Penn 
and Snyder, 1993).  The associated steady-state CO levels are approximately double those 
detected in a typical indoor smoking area (Penn et al. 1994).  This exposure level, while higher 
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than that found in a smoking household, is well below that used in numerous published studies.  
In light of the indirect (in utero) nature of these exposures and the lack of literature on how the 
dose delivered to the fetus varies with the levels of maternal ETS exposure, we selected an 
exposure that we felt would be sufficient to elicit a detectable response while not being beyond 
physiological reality.     
We have carried out multiple ETS exposure in utero experiments with 13-30 mice per 
mixed-gender treatment group (Penn et al. 2007 and unpublished observations).  In these studies, 
there were no demonstrable gender-related differences among offspring in immune responses, 
histopathology, lung function, or clinical pathology.   These results do not predict a significant 
gender difference in gene expression.  Nevertheless, only female offspring samples from our 
earlier study (Penn et al. 2007) were used in the present gene studies to rigorously control for 
subtle, undetected gender influences.  The gene expression results we report here for those 
female offspring correlate well with the pathology and lung function results from that earlier 
study. 
Another recent in utero study demonstrated differential DNA methylation leading to 
modulated gene expression as a result of altered maternal diet (Dolinoy et al. 2006).  No gender 
differences were detected within that study, as well.   Gender differences have, however, been 
reported for some adult responses to in utero stresses.  In an earlier collaborative study, we 
demonstrated that ETS exposure in utero (identical to that used in this experiment) produces 
significant acceleration of atherosclerotic plaque development in male apoE -/- mice (Yang et al. 
2004).  A similar trend existed within female mice, but it did not reach a level of statistical 
significance.  In contrast, there is a report that male, but not female, Balb/c mice that had been 
exposed in utero to mainstream smoke from 1R3F research cigarettes (not ETS from the 1R4F 
cigarettes used here) displayed increased tumor incidence and size associated with decreased 
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cytotoxic T-lymphocyte activity, following injection of EL4 lymphoma cells (Ng et al. 2006).  
These varied gender-effects illustrate the difficulty in predicting adult gender-specific responses 
associated with prior in utero stresses and strongly suggest that different molecular mechanisms 
operate depending on test agent, exposure conditions, subject strain, and experimental endpoints. 
In ESO versus ASO mice, we identified differentially expressed genes that participate 
primarily in cell proliferation, cell motility/elasticity, cell survival, and general cell metabolism 
(Table 3.1).  These biological functions are mediated at the molecular level by down-regulation 
of adhesion/apoptosis signaling molecules, transcription activating DNA-binding motifs, 
ATP/GTP metabolic reagents, and cytoskeletal structural components and binding elements.  
Up-regulated genes contribute to these biological processes through negative regulation of cell 
proliferation, repression of transcription, and chromatin remodeling.  Again, this is accomplished 
through altered adhesion, transcription, metabolism, and cytoskeletal elements 
A single kinase gene (Pik3cd) known to participate in immune and inflammatory 
signaling through Nfκb, Erk, and Mapk pathways was up-regulated in ESO versus ASO mice.  
Nfb, Erk, and Mapk participate in inflammation processes (Roux and Blenis 2004), including 
those in the lung (Wuyts et al. 2003).  Pik3cd also has been linked to the increased vascular 
permeability observed in inflammation (Lee et al. 2006).  Four genes linked to asthma or lung 
inflammation (Arg1, Ccl24, Slc7a2, Mcpt1) that did not pass all the microarray filtering criteria 
were confirmed by qRT-PCR as being up-regulated in ESO versus ASO mice, consistent with an 
enhanced lung response in ETS-exposed mice.  Both Arg1 and Slc7a2 have been implicated in 
arginine metabolism (Zimmermann et al. 2003).  Arginine serves as a substrate for both arginase 
1 and nitric oxide (NO) synthetase.  Thus, increases in arginine metabolism catalyzed by 
arginase 1 are believed to decrease the production of NO via NO synthetase.  Normal relaxation 
of smooth muscle is NO dependent, and decreases in NO are thought to contribute to smooth 
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muscle mediated broncho-constriction, such as that seen in asthma.  Scl7a2 (CAT2) is a cationic 
amino acid transporter involved in arginine transport.  Altered arginine transport affects the 
arginine metabolic pathway and may also alter NO production.  Ccl24 (eotaxin 2) plays a role in 
eosinophil recruitment to the lung in allergic asthma (Panina-Bordignon and D'Ambrosio 2003).  
The Mpct family contains mast cell-specific proteases that participate in mast cell activation and 
degranulation (Small-Howard and Turner 2005).  Changes in cytoskeletal elements and binding 
can confer relaxed cell-to-cell attachment and facilitate infiltration of inflammatory elements.  
The gene expression profile reported here indicates that adult mice exposed in utero to ETS have 
increased lung inflammation in response to OVA relative to in utero air-exposed cohorts.  These 
results support the functional, histopathological and immune system changes we have 
documented in OVA-sensitized and challenged mice (Penn et al. 2007). 
 Figure 3.2 illustrates a literature-based gene network to which our differentially 
regulated gene findings (ESO versus ASO comparison) have been applied.  This network brings 
together, through our data, groups of relationships that become associated for the first time, 
creating a custom network of differential gene response for our experiment.  This custom 
network shows that the differences seen between our treatment groups are based upon 
differential regulation of a dispersed and varied group of genes in clustered relationships with 
inflammatory/asthma genes that are not differentially regulated.  The majority of these 
differentially regulated genes does not have direct ties to the immune system or previously 
defined inflammatory responses. None of the well defined asthma/inflammatory genes (Il1b, Il4, 
Il10, Il13, Il6, Tnfa, Infg, Tgfb1) are differentially expressed, although they connect many of the 
genes that are.  This is not surprising, as the comparison is between two groups (ESO, ASO) that 
both exhibit marked eosinophilic airway inflammation following classic OVA 
sensitization/challenge.  However, the few asthma/inflammatory genes that are differentially 
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expressed (Pik3cd, Arg1, Slc7a2, Ccl24, Mcpt1) are all up-regulated in ETS-exposed mice.  The 
mild enhancement of inflammatory/immune response indicated by these gene changes is 
reflected in the pathophysiological responses of the two groups (Penn et al. 2007) and raises 
concern that ETS may mediate increased inflammatory injury or alter immune response upon 
initial exposure to an infectious agent, such as respiratory syncytial virus (Phaybouth et al. 
2006). 
In EOO versus AOO mice, differentially expressed genes participate in adaptive immune 
responses, cell proliferation and survival, and cell cycle control (Table 3.4).  These processes are 
controlled through down-regulated adhesion, major histocompatibility complexes, immune, and 
pro-inflammatory molecule genes, including cytokines and chemokines.  Up-regulated genes 
influence these processes through alterations in G-protein receptor signaling and cell 
proliferation, differentiation, metabolism, and morphology.  Consistent down-regulation of 
critical inflammatory genes in ETS- and doubly OVA-exposed mice was confirmed through 
qRT-PCR, revealing down-regulation of 17 asthma-related and/or inflammatory genes (Arg1, 
Ccl8, Ccl11, Ccl24, Ear11, Mcpt1, Sprr2a, Chi3l3, Chi3l4, Chia, Slc7a2, Il4, Il6, Il10, Il13, Il1b, 
Tnfa).   
Genes directly or indirectly inhibiting immune responses were up-regulated in EOO 
versus AOO mice.  Genes promoting immune responses were down-regulated, including genes 
for the pro-inflammatory/Th2 cytokines IL1b, IL4, Il6, IL10, IL13, and TNFα.  Pro-
inflammatory cytokine genes (Il1b, Il6, Tnfa) were down-regulated in EOO mice, decreasing 
innate inflammatory potential, as seen in endotoxin tolerance (Cook 1998).  Down-regulation of 
Th2 cytokine genes (Il4, IL10, Il13), as described in our data, has been reported in alloreactive T 
cells in which tolerance has been induced  and immune rejection suppressed (Taylor et al. 2002).  
The gene for IL10, which is essential for the eosinophilic inflammation seen in asthma (and in 
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this mouse model), is down-regulated, resulting in decreases in mucus production and 
eosinophilic inflammation without decreased IgE or IL4 (Yang et al. 2000).   
Changes in non-cytokine immune gene expression also support ETS-associated 
dampening of immune responses in OVA tolerant mice subsequently challenged with OVA 
(Table 3.5).  The product of Hgf suppresses pulmonary dendritic cell antigen-presenting 
capacity, thereby inhibiting the immune response to inhaled allergen (Okunishi et al. 2005).  
Ppapdc2 produces a phosphatase that inhibits PMN activation (Fukunaga et al. 2006).  Rnd3 
product is a Rho GTPase that negatively regulates the polarization and cytoskeletal 
rearrangements that are necessary for leukocyte migration (Sanchez-Madrid and del Pozo 1999).  
Dpp4 protein, CD26, cleaves a number of cytokines involved in leukocyte chemotaxis and 
targeting, as well as in progenitor cell proliferation and recruitment (Boonacker and Van 
Noorden 2003).  This inactivation of cytokines serves to modulate the immune response.   
The type II MHC genes, H2-Ab1 and H2-Eb1, and the type I MHC gene, H2-D1, were 
down-regulated in EOO mice.  Down-regulation of these molecules results in diminished antigen 
presenting capacity (Stevenson et al. 2000; Wolk et al. 2000).  Pro-inflammatory chemokine 
genes Ccl11 (MIP2), Ccl24 (Eotaxin2), Ccl8 (MCP2), Cxcl10 (IP10), and Cxcl2 (GROβ), 
produce chemoattractant ligands for the entire range of white blood cells (Mantovani et al. 2004).  
Their down-regulation would inhibit the attraction and accumulation of effector cells necessary 
for an appropriate immune response. 
The signaling lymphocyte activation molecule (SLAM) family of receptor molecules 
provides signals modulating innate and adaptive responses and polarizing T cells toward Th2 
responses (Graham et al. 2006).  Hence, down-regulation of Slamf8 and Slamf9 would reduce 
Th2-mediated allergic responses.   T cell factor 7 like 2 (Tcf7l2) is produced by T cells and, with 
other T cell factors, participates in T cell development through the Wnt pathway (Willinger et al. 
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2006).  Down-regulation of the Wnt pathway could interrupt the differentiation and maturation of 
T cells.  Slpi is a protease inhibitor gene whose product suppresses the inflammatory action of 
mast cell and PMN proteases (Wright et al. 1999).  Suppressor of T cell signaling gene (Sts1) 
protein negatively regulates the T cell receptor (TCR), thereby dampening the immune response 
even in the face of antigen-TCR binding (Carpino 2004).  ADAM8, a disintegrin 
metalloprotease, catalyzes cleavage of CD23 (low affinity IgE cell surface receptor).  The 
resulting soluble CD23 causes up-regulation of IgE and inflammatory cytokine production 
(Fourie et al. 2003); therefore, down-regulation of Adam8 diminishes inflammatory response.  
Inducible TGFβ (Tgfbi) has a direct positive regulatory effect on production of the pro-
inflammatory cytokine, IL6 (Moller et al. 1994).  Down-regulation of Tgfbi decreases IL6 and 
consequently inflammation.  Capg down-regulation alters actin filament capping, disturbs the 
cytoskeleton, and results in reduced macrophage motility and phagocytosis (Parikh et al. 2003).  
Sirpa produces an immunoglobulin superfamily protein that inhibits phagocytosis receptors on 
macrophages and diminishes the innate immune response.  Itgax codes for one chain of the 
heterodimeric mature dendritic cell integrin, CD11c.  This molecule is critical to maturation of 
the dendritic cell into an antigen presenting cell, and down-regulation would decrease the 
recognition and uptake of antigen by dendritic cells (Hebel et al. 2006).  C1QC is a subunit of the 
recognition member of the complement cascade that promotes antigen recognition, isolation, and 
up-take (Sontheimer et al. 2005).  Down-regulation of the gene responsible for this molecule 
would help suppress innate immune response. 
 All alterations in expression functionally support inhibition or, more correctly, 
dampening of the immune response.  The only apparent inconsistency among genes influencing 
the immune response was an up-regulation of Ccrl1, which encodes a receptor for dendritic and 
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T cell cytokines involved in chemotaxis (Gosling et al. 2000).  However, the possibility of Ccrl1 
involvement in specific negative regulation of dendritic and/or T cells cannot be eliminated.   
Almost all differentially expressed genes participating in the immune, inflammatory, and 
asthma reactions are modulated toward reduced responsiveness in the mice that were exposed to 
ETS in utero (EOO versus AOO).  The effect of this differential expression--decreased antigen 
presenting capacity and dampened immune signaling--implies decreased innate and adaptive 
immune responses to new challenges, as well as reduced inflammation.  Previously, we 
demonstrated these dampened responses in OVA-tolerized mice that were subsequently 
sensitized and challenged (Penn et al. 2007).   
Figure 3.3 illustrates a literature-based network of relationships between differentially 
expressed genes that we identified in the EOO versus AOO comparison.   This network connects, 
through our data, groups of previously described relationships that have not been previously 
associated.  The resulting custom network demonstrates that the significant, observed, immune 
response differences seen in this comparison (EOO versus AOO) are related to differential 
regulation of genes that collectively suppress immune responsiveness.  In Figure 3.3, major 
inflammatory/immune genes (Il1b, Il4, Il10, Il13, Il6, Tnfa) that are down-regulated in EOO 
mice relative to AOO mice connect many up- and down-regulated genes that negatively regulate 
the immune response.  The specificity of this suppressive modulation is of concern.  Would 
exposure to alternate antigens within this environment of immune down-regulation elicit 
appropriate innate and/or adaptive responses?   Agents, identified by MHC molecules or 
neutralized by effector cells that are down-regulated by ETS exposure in utero, could escape 
detection or elicit sub-optimal immune responses. 
While our main interest was on the effect of ETS exposure in utero on lung responses to 
OVA in both sensitized and tolerized mice, it is noteworthy that the number and magnitude of 
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differences between ESO and EOO mice greatly exceed those between ASO and AOO mice 
(Tables 3.2 & 3.3).  In all the asthma-related genes examined, ESO-EOO differences were 
consistently greater (qRT-PCR) than ASO-AOO differences.  This net effect is a result of the 
mild to moderate increase in responsiveness of ESO mice compared to ASO mice and the much 
greater suppression of response in EOO mice relative to AOO mice.  The relative responsiveness 
or reactivity of these 4 groups of mice, indicated by their general gene expression profiles as well 
as by their relative expression of specific asthma/inflammatory genes, is supported by 
histopathology, BAL cell counts and cytokine analyses, immunoglobulin levels, and AHR (Penn 
et al. 2007).  In each comparison, additional candidate genes (white nodes in Figures 3.2 & 3.3) 
warrant future investigation.   
In our comparison of gene expression between ESO mice and ASO mice, it was evident 
that genes for cell proliferation, growth, and general metabolic processes were more suppressed 
in the most reactive group (ESO).  Inflammation is associated with proliferation of innate and 
adaptive immune cells.  However, activation of the p38 pathway  (Diehl et al. 2000) and Pik3cd  
(Donahue and Fruman 2004) can result in cell cycle arrest and halt cell proliferation and growth 
in lymphocytes.  Findings in the EOO versus AOO mice indirectly support the findings in ESO 
versus ASO mice.  The least responsive group (EOO) had a differential expression profile that 
was indicative of increased cell proliferation, growth, and metabolism.  Since our lung samples 
represent total lung RNA, proliferation status of non-immune cells is also reflected in the 
differential expression.  Fibroblasts have been implicated in maintenance of the local 
environment (extracellular matrix) within tissues, including down-regulation of inflammatory 
responses (Buckley et al. 2001).  Proliferation of regulatory fibroblasts might overshadow down-
regulation of proliferation in immune cells. 
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The fate of T cells, activation or anergy, has been tied to both cell cycle progression 
(Wells et al. 2000) and intracellular calcium flux (Gavin et al. 2002). Evidence for regulation of 
both the cell cycle and of ion channels is presented in our data (Tables 3.1 & 3.4).  The ultimate 
fate of the immune response will depend on the character of the T cells involved (T effectors 
versus T regulatory) as well as on the presence of co-stimulators, MHC expression, and innate 
immune elements.  An attenuation of innate and adaptive responses, if non-specific, might 
threaten the ability of the least responsive group (EOO) to respond appropriately to an infectious 
agent.  Likewise, excessive airway inflammation might impair defenses or increase injury during 
infection (Beisswenger et al. 2006) in the most responsive group (ESO).  Thus, either extreme of 
the ETS-based responsive dichotomy may be undesirable (Clark and Kupper 2005).  
Our data comparing two aerosol-tolerized groups (EOO, AOO) illuminate the complexity 
of immune tolerance.  The dynamic nature of tolerance, involving the down-regulation and 
inhibition of numerous biological processes that collectively potentiate the immune system, is 
well illustrated by our data.  While anergy of specific T cell lines plays a significant role in 
tolerance, many other “players” (dendritic cells, PMN‟s, mast cells, macrophages, and 
eosinophils) are suppressed via multiple mechanisms, including structural and enzymatic 
changes yielding functional impairments.  In vivo, tolerance is the sum of suppressed 
stimulation/activation (decreased antigen presentation, T cell anergy, dampened intracellular 
signaling) and impaired effector function (depressed chemotaxis, protease inhibition, suppressed 
cell mobility).  Our data define multiple sites and diversities in mechanisms involved in 
inhibiting the immune system and achieving tolerance.  
This study also demonstrates that varying degrees of responsiveness can exist within the 
tolerant population.   While both EOO and AOO mice demonstrated no IgE or eosinophilic 
inflammation (and thus were considered tolerant), the AOO mice had higher levels of Th2 
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cytokines, BAL inflammatory cells, airway hyperresponsiveness, and airway pathology and in 
many of these cases the differences were significant (Penn et al. 2007).  Differential gene 
expression data reveal more gene alterations inhibiting the immune response in EOO versus 
AOO mice.  These differences, initiated by an environmental exposure limited to the gestational 
period, may not be totally antigen-specific and therefore are potentially detrimental.  Certainly, 
the difference between responsiveness in EOO and AOO mice is a reflection of the mechanisms 
involved in tolerance induction.   
Alteration of gene expression mediated by in utero environmental exposure represents a 
change in phenotype determined by gene-environment interaction.  While the mechanism by 
which these gene expression changes are orchestrated is not yet defined, epigenetic involvement 
is likely (Drake et al. 2005; Rahnama et al. 2006; Waterland and Jirtle 2003).  Given the number 
and variety of genes that we found to be differentially regulated along with the indirect and 
relatively mild nature of exposures that culminated in demonstrable response differences in 
immunology, histopathology, clinical pathology, and lung function, the search for single 
candidate genes may need to evolve to an examination of global epigenetic alterations.  In most 
instances, gene-environment interactions may cause transient, reversible, or non-critical 
alterations in gene expression, or no detectable change in phenotype.  However, the ability of 
relatively mild in utero environmental exposures during embryonic development to modulate 
adult gene expression may move chronic adult diseases (atherosclerosis, obesity, diabetes, 
allergy, asthma) into the realm of early developmental disorders, such as childhood diabetes, 
leukemia, and autism that also appear to be environmentally modulated. 
Genes recognized in this study are present in other tissues and may have varied and 
diverse functions beyond those described here.  However, the functions delineated within this 
study are consistent with the pathologic and physiologic differences defined by the study 
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exposures.  Gene ontogeny has been examined in context of the complexity of an in vivo system.  
Further refinement of specific cell types involved and specific mechanisms of differential gene 
regulation are ongoing, particularly gene-specific and global changes in epigenetic 
modifications. 
CONCLUSION 
 In utero ETS exposure alters gene expression in the lung of adult BALB/c mice in 
response to OVA exposure, regardless of whether that exposure was sensitizing or tolerizing.  
The results support a gene-environment interaction that results from ETS exposure in utero and 
that alters the phenotype of adult mice as defined by their gene expression and inflammatory 
responses to an allergen (OVA).  The strength of these findings is re-enforced by the consistency 
of relative group responses across gene expression data, airway function (reactivity) changes, 
presence of airway inflammatory mediators (cytokines, cells), and lung histopathology.  Our data 
implicate milder, wide-spread gene expression changes rather than (or in addition to) larger more 
discrete alterations in single gene expression as the mechanism through which these in utero 
exposures alter adult lung responses. 
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CHAPTER 4 
 
EXPOSURE TO ENVIRONMENTAL TOBACCO SMOKE IN UTERO ALTERS GENE 
EXPRESSION IN THE ADULT LUNG IN THE ABSENCE OF HISTOPATHOLOGY 
 
INTRODUCTION 
 Human epidemiology studies and experimental animal studies have implicated various in 
utero exposures to subsequent adult disease (Baraldi et al. 2002; Barker 1995).  Experimental 
studies have demonstrated phenotypic and gene expression changes in adult animals mediated by 
prenatal exposure to different environmental toxins (Holladay 1999; Yang et al. 2004).  These 
studies have reported gene expression changes seen with the identification of an altered 
phenotype.  Gene expression changes associated with altered phenotype help define that 
phenotype change.  However, these expression changes hold no clue to the initiating events that 
lead to change in phenotype.   
The inception of gene expression changes occurs at the time of exposure.  For most 
developmental and complex diseases, the ability to recognize these early changes is undeveloped 
because we do not yet understand the complex interactions and multiple pathways involved in 
progression of these diseases.  Therefore, the mechanisms through which these changes take 
place are difficult to define.  Time series studies that look for changes at time points prior to 
identification of the new phenotype are a first step towards identifying initiating changes.  In 
designing our study, several early time points were included in an attempt to determine early 
gene expression changes associated with altered phenotype. 
We have previously reported on changes in immune responses induced in 15 week-old 
mice by exposure to environmental tobacco smoke (ETS) in utero subsequently challenged with 
the allergen, ovalbumin (OVA).  Our studies showed ETS-related changes in bronchoalveolar 
lavage (BAL) fluid cytokine levels and differential cell counts, plethysmography defined airway 
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responsiveness, and lung histopathology (Penn et al. 2007) and gene expression (Rouse et al. 
2007).  Changes in lung function, physiology, and histopathology were consistent with and at 
least partially explained by the demonstrated gene expression changes.  At earlier time points (0, 
6, and 10 weeks of age), no consistent significant differences were detected in BAL fluid or 
histopathology.  Minor differences between in utero ETS- and AIR-exposed mice were found in 
airway responsiveness (as measured by plethysmography at 6 and 10 weeks of age).  However, 
no other significant differences were seen (Penn et al. 2007). 
 Although functional changes were minimal and physical changes undetected at these 
earlier times, the molecular alterations mediated by ETS exposure in utero that lead to 
subsequent differences in physical and functional endpoints at 15 weeks of age must be present 
at these times.  We examined gene expression at these earlier time points in an attempt to detect 
the etiology of changes demonstrated at 15 weeks.   
MATERIALS AND METHODS  
Animal Protocols 
  
Eight-week old BALB/c mice (Harlan, Indianapolis, IN), were housed and handled 
according to the Guide for the Care and Use of Laboratory Animals (Institute of Laboratory 
Animal Resources. 1996. Washington D. C., National Academy Press).  The Louisiana State 
University Institutional Animal Care and Use Committee approved all animal procedures.  All 
animals were handled humanely and care was taken to assure alleviation of pain and suffering.  
A barbiturate solution (Beuthanasia-D, Schering-Plough, Kenilworth, NJ) was used via 
intraperitoneal injection (0.2 ml per mouse) for all sacrifices. 
Exposures  
 
Pre- and post-natal exposure protocols have been described in detail (A Penn et al. 2007).  
Briefly, pregnant mice were exposed in dynamic exposure chambers to either ETS mixed with 
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HEPA-filtered air (ETS) or to HEPA-filtered air (AIR) 5 hours per day for days 1-19 of 
gestation.  ETS exposures had average final concentrations of total solid particles n =10mg/m
3 
and CO = 44.5 ppm.  Ten mice from each group were sacrificed at one day of age (neonates).  At 
6 weeks of age, eight males and eight females were sacrificed from each group (ETS, AIR).  Half 
of the remaining mice from each of these groups inhaled 1% OVA aerosol (20 min/day; 10 days; 
7-8 weeks of age) to produce tolerance, while the other half inhaled saline aerosol.  All mice 
were OVA-sensitized and challenged, then sacrificed one day following final challenge at 15 
weeks of age to determine the effects of ETS exposure in utero on responses to OVA 
sensitization/challenge in mice not previously exposed to OVA (ESO, ASO) and on OVA 
tolerance in mice previously exposed to OVA (EOO, AOO).   No offspring were exposed to ETS 
after birth.   
Lung Harvest and mRNA Extraction 
 
 Left lung lobes were excised, placed in RNAlater (Ambion, Austin, TX), and stored at -
80°C.  Subsequently, these samples were transferred to 1mL TRIzol (Invitrogen, Carlsbad, CA) 
and homogenized using a Mixer Mill MM 300 (Qiagen, Valencia, CA) with a copper bead.  
Chloroform was added to the homogenate, mixed by inversion, and centrifuged @ 4°C to 
separate phases.  The RNA-containing aqueous phase was transferred to an RNeasy Micro Kit 
(Qiagen, Valencia, CA).  The manufacturer‟s protocol was followed, omitting Buffer RLT.  
Remaining DNA was eliminated using a column RNase-Free DNase Set (Qiagen, Valencia, CA).  
An additional Buffer RPE wash was used to remove residual salts followed by an additional 2 
minute spin to evaporate residual ethanol. 
 RNA samples were checked for quantity and purity with a NanoDrop ND-1000 
Spectrophotometer (NanoDrop, Wilmington, DE).  Values generated from the NanoDrop for all 
samples fell into the following ranges, 260/280 ratio: 2.09-2.17, 260/230 ratio: 2.20-2.27, 
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concentration: 1200-1900 ng/uL.  Further quality assays were performed on 1:5 dilutions of 
RNA samples with an Agilent 2100 BioAnalyzer (Agilent Technologies, Palo Alto, CA) and 
Agilent RNA 6000 Nano Series II Kits.  All samples fell into the following ranges, 28S/18S 
ratio: 1.3-1.8, RNA Integrity Number: 8.5-9.6. 
Microarray Assay 
 
 Individual Affymetrix Mouse MOE 430A Arrays were used to assess neonatal gene 
expression in each of six mice from both groups (ETS or AIR).  Sex was not determined at 
sacrifice and was therefore random in the neonatal microarray analysis.  At 6 weeks of age, gene 
expression in each group (ETS, AIR) was assessed on 6 microarrays.  Four females of each 
group were hybridized to 3 microarrays, one array with 2 samples pooled and 2 arrays with 
individual samples.  Likewise, 4 male samples from each group were hybridized to 3 
microarrays, one array with 2 samples pooled and 2 arrays with individual samples.  The 4 
groups (ES, AS, EO, AO) analyzed at 10 weeks of age were examined using 7 to 10 microarrays 
per group representing 11 to 19 mice (Table 4.1).  
 Double stranded cDNA synthesized from total RNA was used to create cRNA, which 
was then biotinylated, fragmented, and added to a hybridization cocktail that included probe 
array controls, bovine serum albumin, and herring sperm DNA.  This cocktail was then 
hybridized (16 hours; 45°C) to oligonucleotide probes on a GeneChip Mouse MOE  430A  Array 
in a GeneChip Hybridization Oven 640.  Immediately following hybridization, the array 
underwent an automated washing and staining protocol on a GeneChip  Fluidics  Station and was 
scanned with a GeneChip Scanner 3000.    Data collection and processing of initial raw data 
were performed by a GeneChip Workstation.  All gene chips and instrumentation were from 
Affymetrix (Santa Clara, CA).  Probe hybridization and cDNA synthesis were performed at the 
LSU Health Sciences Center in New Orleans in the spring of 2005. 
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Table 4.1:  Number of Microarrays and Samples Used for 10 Week Analysis   
Samples         AO         EO         ES        AS 
 Male Female Male Female Male Female Male Female 
single 1 5 2 1 1 2 1 1 
2-pooled 1 2 2 5 2 3 1 6 
3-pooled       1  
         
arrays 2 7 4 6 2 5 3 7 
mice 3 9 6 11 3 8 6 13 
 
Gene Expression Analysis  
 
 GeneChip Workstation data were sent to Expression Analysis Systems (Durham, NC).  
Initially, a principle component analysis was used to determine clustering of experimental units.  
The analysis revealed clustering by treatment group with greater variation between groups than 
within groups (data not presented), thus validating subsequent comparisons between treatment 
groups.  Prior to making these comparisons, data were subjected to reduction of invariant probes 
(REDI) to remove previously determined mal-performing probes from the data set.  Pairs of 
treatment group data underwent permutation analysis for differential expression (PADE)
 
that 
accounts for false positives by tabulating a false discovery rate (FDR) based on a permutation-
generated reference curve (technical information on REDI and PADE analyses available at 
www.expressionanalysis.com).  Following REDI and PADE, expression data were tabulated for 
each remaining transcript, including individual transcript p-value, FDR, fold change, Affymetrix 
probe ID, gene symbol, and functional summary.  All transcripts included in this study had a fold 
change of at least 1.5 (up or down), and both an individual p-value and FDR <0.05. 
Pathway Analyses  
 
 Gene expression data were analyzed with the network- and pathway-building software, 
Ingenuity Pathways Analysis 4.0; gene networks and canonical pathways were examined using 
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the Ingenuity Analysis Knowledge Database (Ingenuity Systems, Redwood City, CA).  Identified 
networks and pathways were scrutinized for phenotypic relevance.  Select genes were identified 
from the literature for confirmation by quantitative real-time PCR analysis.  Custom networks 
were created to demonstrate the connections between the genes identified in our expression 
analyses.  
PCR Confirmation 
 
PCR confirmation of gene expression changes in these samples was not possible.  These 
samples were stored in -80°C freezers at LSU Health Sciences Center in New Orleans, Louisiana 
at the time of Hurricane Katrina and were subsequently lost after the prolonged loss of electricity 
and the inaccessibility of the samples.  However, with some exceptions (detailed in our earlier 
publication; Rouse et al, 2007), later samples demonstrated consistency between microarray and 
PCR findings.   
NEONATE: ONE TO THREE DAYS OF AGE 
Table 4.2:  ETS Exposure In Utero Suppresses Angiogenesis and Tissue Growth Factors in 
Neonates 
 
 
Results 
 
 When the relatively stringent criteria described in Materials and Methods was applied to 
neonatal gene expression data, only 4 genes (Table 4.2) were differentially expressed between 
neonates receiving ETS in utero versus those receiving AIR in utero.   
Affymetrix 
ID 
Fold 
change FDR p-value 
Gene 
Symbol Function Process 
1436448_a_at -1.50 0.000 0.0003 Ptgs1 (Cox-1); prostaglandin synthesis  angiogenesis control 
1452114_s_at -1.71 0.000 0.0009 Igfbp5 enhances growth factors secretion growth, proliferation 
1449319_at -2.05 0.000 0.0044 Rspo1 Unknown  Wnt signaling 
1423954_at -2.16 0.000 0.0050 C3 Endopeptidase inhibitor Complement activation 
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Discussion 
 
 Although only 4 genes passed all of the screening criteria, these genes could have 
significant impact on lung structure and function.  Ptgs1 produces a protein that is essential for 
constitutive synthesis of prostaglandin E2 which plays a critical role in specific lymphocyte 
development (Carey et al. 2003) and angiogenesis (Jones et al. 1999).  Igfbp5 plays a role in 
cellular growth and proliferation through its interaction with insulin-like growth factor (Laursen 
et al. 2007) and has independent effects on extracellular matrix (Pilewski et al. 2005).  Rspo1 
protein is believed to function in Wnt-signaling (Kamata et al. 2004) which is associated with 
embryonic development and adult tissue homeostasis.  The C3 protein is needed for activation of 
both the classical and alternative complement pathways.  Complement activation is an innate 
immune response to infection or injury (Thurman et al. 2007; Walters et al. 2002). 
SIX WEEKS OF AGE 
Results 
 
 At 6 weeks of age, only 2 genes passed the filtering criteria, Sult1a1 and Klf15.  The 
protein of Sult1a1 is an enzyme that conjugates sulfur to phenol or phenol-like compounds, 
including drugs, xenobiotics, hormones, and neurotransmittors (Windmill et al. 1998).  Klf15 
produces a transcription factor that has been implicated in glucose regulation (Gray et al. 2002) 
and adipocyte differentiation (Mori et al. 2005).  Both of these genes had FDR‟s < 0.000 and 
Sult1a1 p-value was less than 0.0000 while p-value of Klf15 was equal to 0.0019.  Both genes 
were up-regulated (Sult1a1 1.69 and Klf15 1.73). 
Discussion 
 
 While the 2 genes up-regulated by in utero ETS exposure at 6 weeks of age could 
potentially have significant functional effects through metabolism of xenobiotics (Sult1a1) or the 
regulation of glucose (Klf15), neither gene has been previously associated with either the disease 
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processes or the endpoints examined within this study (allergy, asthma, pulmonary inflammation, 
or the immune system).  Certainly, this does not preclude them participating in the responses 
described at later time points.  However, we have no solid basis for implicating them at this time. 
TEN WEEKS OF AGE 
Results 
 
 Using pre-determined filtering criteria (fold change ≥ 1.5, FDR < 0.05, transcript p-value 
< 0.05), 12 transcripts were found to be differentially regulated (all up-regulated) following 
REDI and PADE analyses of raw Affymetrix data from ES versus AS mice.  Following removal 
of duplicate transcripts and undefined or unmapped transcripts, 9 unique genes were found to be 
up-regulated (Table 4.3).  In this gene list, fold-change in expression ranged from 3.28 to 1.59, p-
value from 0.0021 to 0.0194, and FDR from 0.000 to 0.047.   
 When similarly filtered following REDI and PADE analyses, the raw data from EO 
versus AO mice revealed 16 differentially regulated transcripts (6 up-regulated and 10 down-
regulated).  Removal of duplicate and unmapped transcripts yielded 9 unique genes (3 up-
regulated and 6 down-regulated) in mice exposed to OVA (Table 4.4).   Expression fold-change 
in these genes ranged from 2.17 to 1.54 and from -1.50 to -3.58, p-value from < 0.0000 to 
0.0024, and FDR‟s were all < 0.000.  Confirmation via qRT-PCR was not possible with these 10 
week samples.  All RNA samples and cDNA derived from these samples were stored in New 
Orleans at the time of Hurricane Katrina and were subsequently lost.  
Differential expression data revealed that small gene networks significantly affected in 
both ES versus AS and EO versus AO comparisons.  These networks are represented in Figures 
4.1 and 4.2, respectively.  All of the differentially regulated genes in the OVA-exposed mice (EO 
vs. AO) were identified within a network.  Only 6 of the genes from the ES versus AS 
comparison were found within a single network, one gene was identified but was outside the 
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network, and two genes were not related to any of the other genes.  Since very few genes met all 
of the filtering criteria, identification of significant canonical pathway involvement was not 
attempted in either comparison. 
 
 
Table 4.3:  Differentially Expressed Genes in ES Mice versus AS Mice are Pro-
Inflammatory and Metabolic Response Genes 
 
 
 
 
 
Table 4.4:  Differentially Expressed Genes in EO Mice versus AO Mice Represent Stress 
Response Genes. 
 
Affymetrix 
ID 
Fold 
Change FDR p-value 
Gene 
Symbol 
 
Function 
 
Process 
1438211_s_at 2.17 0.000 0.0001 Dbp Activate transcription  Control of Cyp2a4 
1419248_at 1.69 0.000 0.0001 Rgs2 Signal transdution Regulation of G-protein signaling 
1422122_at 1.54 0.000 0.0000 Fcer2a Low affinityIgE binding  B-cell activation & proliferation 
1422474_at -1.50 0.000 0.0006 Pde4b cAMP hydrolase Second messenger signaling 
1416288_at -1.62 0.000 0.0010 Dnaja1 Protein folding/binding Nrf2-mediate oxidative stress response 
1416755_at -1.66 0.000 0.0004 Dnajb1 Protein folding/binding Nrf2-mediate oxidative stress response 
1416077_at -2.00 0.000 0.0002 Adm Hormone Hypotension & cell proliferation 
1452388_at -3.17 0.000 0.0009 Hspa1a Protein folding/binding Stress response 
1427126_at -3.58 0.000 0.0024 Hspa1b Protein folding/binding Stress response 
Affymetrix ID 
Fold 
Change FDR p-value Gene Symbol 
 
Function 
 
Process 
1448872_at 3.28 0.000 0.0021 Reg3g Proteoglycan binding Anti-microbial 
1449434_at 2.37 0.022 0.0101 Car3 Carbonate dehydratase Single carbon metabolism 
1422651_at 2.36 0.047 0.0194 Adipoq Hormone activity Fatty acid metabolism  
1451263_a_at 2.27 0.047 0.0153 Fabp4 Fatty acid binding Pro-inflammatory 
1417867_at 2.03 0.022 0.0111 And (Cfd) Peptidase Complement activation 
1424737_at 1.98 0.022 0.0080 Thrsp Transcription regulator Lipid metabolism 
1415994_at 1.93 0.022 0.0112 Cyp2e1 Monooxygenase Xenobiotic metabolism 
1422230_s_at 1.64 0.022 0.0050 Cyp2a Monooxygenase Xenobiotic metabolism 
1449319_at 1.59 0.022 0.0056 Rspo1 Unknown Wnt signaling 
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In addition, we could study differences between mice that had ETS exposure in utero or  
 
 
Discussion 
 At birth, offspring had only been exposed to ETS or AIR in utero.  Perinatal gene 
expression analysis examined ETS-mediated constitutive differences in gene expression.  At 6 
weeks, offspring had only been exposed to ETS or AIR in utero.  Therefore, 6-week gene 
expression analysis evaluated ETS-mediated constitutive differences in gene expression at an 
Figure 4.1:  Pro-Inflammatory Network of Genes Up-Regulated in Ten-Week Old ES 
Mice versus AS Mice.   Green represents down-regulation and red up-regulation 
(fold-changes ≥ 1.5); white nodes represent fold-change < 1.5.  Intensity of color 
increases with increasing fold-change (numbers represent fold-change values).  
Dotted lines indicate indirect relationships and solid lines direct interactions.  All 
gene symbols are human homologue designations.  Network constructed with 
Ingenuity Systems software.  For explanation of nodes shapes see Figure 3.2 or 3.3 in 
Chapter 3. 
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additional time point and in a more mature developmental state.  By 10 weeks of age, mice 
had been challenged with either OVA or saline aerosol.  Examination at this point investigated 
changes that occur in the course of producing OVA-tolerance (AS vs. AO and ES vs. EO), as 
well as the effect of ETS exposure in utero on the development of OVA-tolerance (EO vs. AO).  
AIR exposure in utero and were then given mild respiratory perturbation (in this case, 
aerosolized saline) by examining ES vs. AS.  
 
 
 
 
 
Figure 4.2:  Stress Response Gene Network Primarily Down-Regulated in Ten-
Week Old EO Mice versus AO Mice.  Green represents down-regulation and red 
up-regulation (fold-changes ≥ 1.5); white nodes represent fold-change < 1.5.  
Intensity of color increases with increasing fold-change (numbers represent fold-
change values).  Dotted lines indicate indirect relationships and solid lines direct 
interactions.  All gene symbols are human homologue designations.  Network 
constructed with Ingenuity Systems software.  For explanation of nodes shapes 
see Figure 3.2 or 3.3 in Chapter 3. 
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At 10 weeks of age, the few gene expression differences noted suggest that ETS-exposure 
in utero alters gene expression in juvenile mice.    In comparing ES mice with AS mice, all of 
the significantly altered genes (passing the filtering criteria) are up-regulated and are directly or 
indirectly associated with Tnf (Figure 4.1).  Two genes (Reg3g, Rspo1) that are significantly up-
regulated do not appear in the gene network.  Reg3g is a gene whose product is not well defined 
but has been described as an acute phase, inflammatory molecule that binds proteoglycans and 
through that binding has an anti-microbial effect (Cash et al. 2006).  The product of Respo1 has 
unknown molecular function but has been theorized to bind to iron or sulfur elements within 
organic molecules, resulting in Wnt signaling (Kamata et al. 2004).  Of the 7 remaining genes, 4 
(Adipoq, Fabp4, Adn, Thrsp) are related to lipid metabolism and have been associated with 
mediation of inflammatory conditions.  The protein of Adipoq (adiponectin) increases insulin 
sensitivity and has anti-inflammatory and anti-atherogenic effects.  Fatty acid binding protein 4 
(product of Fabp4) has been implicated in macrophage cholesterol metabolism and the ability of 
macrophages to mount an inflammatory response (Makowski et al. 2005).  The protein product 
of Adn, or adipsin, is also known as complement factor D and is essential for activation of the 
alternate pathway.  Defects in adipsin have been associated with accumulation of immune 
complexes (Abrera-Abeleda et al. 2007).  Thrsp protein, SPOT14, mediates de novo lipogenesis 
in specific tissues (LaFave et al. 2006).  Car3 protein is found in skeletal muscle, adipocytes, and 
hepatocytes where it is one of several isoforms that function in CO2 metabolism (Kim et al. 
2004).  Two cytochrome p450 genes (Cyp2a5, Cyp2e1) were up-regulated in ETS exposed mice.  
Both of these genes produce enzymes previously shown to metabolize nitrosamines (Pelkonen et 
al. 2000; Seree et al. 1996), a major component of cigarette smoke.  The genes up-regulated by 
in utero ETS exposure collectively represent slight enhancement of lipid-associated immune 
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responses and metabolism of organic nitrogen, especially nitrosamines which are ETS 
components.  
In comparing OVA exposed mice (EO vs. AO), the majority of altered genes are down-
regulated and are involved in cellular stress and immune responses.  The network of EO mice 
versus AO mice (Figure 4.2) shows a prevalence of heat shock protein (HSP) genes, Il2, and Ifng 
in its center.   There are three up-regulated genes (Dbp, Rgs2, Fcer2a) in the network.  Dbp 
protein positively controls Cyp2a expression (Gachon et al. 2006).  The protein product of Rgs2 
is a modulator of G-coupled protein receptor signaling associated with control of vascular 
smooth muscle contraction and hypertension (Tang et al. 2003).  Fcer2a produces CD23 the low 
affinity binding molecule for the Fc region of IgE that could be instrumental in modulating 
allergic immune responses (Ford et al. 2006).  Six genes (Pde4b, Dnaja1, Dnajb1, Adm, Hspa1a, 
Hspa1b) are down-regulated in the network.  Pde4b is the predominant phosphodiesterase in 
immune cells and is essential to LPS-mediated release of the pro-inflammatory cytokine, TNF 
(Jin and Conti 2002).  Down-regulation of Pde4b would decrease the innate inflammatory 
response.  Adm produces a hypotensive peptide found in airway smooth muscle cells where 
disruption of the gene results in smooth muscle cell hyperplasia and hyper-responsiveness 
(Yamamoto et al. 2007).  The remaining down-regulated genes are HSP genes from the HSP40 
family (Dnaja1, Dnajb1) or the HSP70 family (Hspa1a, Hspa1b).  The protein products of these 
genes work together chaperoning new proteins for folding and damaged proteins for re-folding 
(Yoneda et al. 2003).  They have also been implicated in apoptosis signaling and facilitation of 
antigen presentation through their interaction with damaged cellular proteins (Kobayashi et al. 
2000).  The genes altered in EO mice versus AO mice support a composite effect of altered 
immune signaling and suppressed HSP function. 
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CONCLUSION 
Results at birth indicate that without any additional local or systemic treatment or 
perturbation there are no detectable differences in gene expression traceable to in utero ETS 
exposures.  Two points to consider in evaluating findings at this time point are; 1) the influence 
on microarray results of the extensive developmental RNA production seen at this time; 2) the 
stringent filtering criteria used to determine gene expression in our study carries an increased 
possibility or false negative results.  Relaxation of filtering criteria (especially FDR) might yield 
valid and essential results presently discarded. 
Results at one day of age and at 6 weeks of age, demonstrate that ETS exposure in utero 
yields no constitutive changes in gene expression.  At each time point, there was no alteration in 
gene expression as defined by the rather stringent criteria outlined in Materials and Methods.  At 
10 weeks of age, mice that have had no allergen (OVA) exposure but that did receive an airway 
perturbation (saline aerosol) exhibit altered gene expression related to their ETS exposure in 
utero.  The changes seen support an airway environment predisposed toward inflammation and 
metabolism of nitrosamines, such as those in cigarette smoke.  Mice that have had aerosol OVA-
challenge prior to 10 weeks of age also demonstrate differential gene regulation based on their 
ETS in utero experience.  In this case, the gene changes suggest an airway with impaired stress 
responses, and altered immune responses, as well as potential up-regulation of nitrosamine 
metabolism. 
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CHAPTER 5 
 
CONCLUSIONS ON THE EFFECTS OF ENVIRONMENTAL TOBACCO SMOKE 
EXPOSURE IN UTERO IN A MURINE MODEL OF HUMAN ASTHMA AND 
THOUGHTS FOR FUTURE STUDIES 
 
 
CONCLUSIONS 
These experiments in a BALB/c mouse model of human asthma investigate the effects of 
environmental tobacco smoke (ETS) exposure in utero on allergen-specific immune responses in 
the lungs of adult offspring.  Results demonstrate altered immune responses in adult mice that 
received ETS exposure in utero.  ETS-associated changes in immune response are seen as an 
enhanced primary response to an allergen, ovalbumin (OVA).  ETS exposure in utero does not 
alter establishment of immune tolerance or sensitization, nor does it alter basic lung structure or 
constitutive gene expression within the lung.   
Mice exposed to ETS in utero demonstrate an increased sensitivity to i.p. injections of 
allergen (ESO vs. ASO) at 15 weeks of age.  Mice exposed to ETS in utero and to allergen 
aerosol at 7 to 8 weeks of age show an increased resistance to i.p. sensitization at 15 weeks of 
age (EOO vs. AOO).  Therefore, the development of immune sensitization or tolerance is not 
altered, but the magnitude of these responses is changed, based upon whether or not there was 
ETS exposure in utero.   
Airway responsiveness, bronchoalveolar lavage cytokines and cytology, histopathology, 
and gene expression results all provide evidence for enhanced initial responses to allergen.  ETS 
exposure in utero yields enhanced airway hyperresponsiveness (AHR) upon initial allergen 
exposure (EO and ES at 10 weeks of age; ESO at 15 weeks of age).  BAL cytology and 
cytokines and histopathology data mirror the results described for AHR at 15 weeks of age.  No 
appreciable changes are seen in the non-AHR endpoints at 10 weeks of age.  Major changes in 
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gene expression are detected only after induced respiratory stress, or perturbation.  The gene 
expression changes described following respiratory perturbation (ES vs. AS and EO vs. AO at 10 
weeks of age; ESO vs. ASO and EOO vs. AOO at 15 weeks of age) reflect, both in process and 
in magnitude, the non-genetic changes seen as a result of ETS exposure in utero.  In some cases, 
the changes in individual non-genetic endpoints are relatively minor or do not achieve statistical 
significance.  However, in all cases, when viewed comprehensively, these alterations are 
sufficient to define a consistent, statistically significant change in response linked to ETS 
exposure in utero.   
 Certainly, the changes seen in all of the major endpoints are determined prior to their 
actual measurement especially are probably set in motion during the ETS exposure in utero.  
This is supported by the fact that adult ETS exposure does not yield the same changes.  
Therefore, timing of the in utero exposure relative to fetal development is essential to defining 
the molecular mechanism through which alterations are achieved.  In this study, we did not 
attempt to narrow the exposure window, and thereby, more closely define the critical point(s) of 
exposure. 
 We did attempt, however, to detect changes prior to and during exposures to OVA.  
Neonatal gene expression changes indicate that some key factors in immune responses are 
changed at birth, prior to OVA exposure.  Given the stringent criteria for acceptance (present in 
all samples, p<0.05, FDR<0.05, fold-change ≥ 1.5), it is not surprising that only a few genes are 
described as altered in expression.  However, the majority of these genes have functions that 
would be consistent with alterations in immune response.  For the most part, constitutive 
expression may not be different between treatment and control mice in this study.  Differences 
may only become demonstrable with additional respiratory system perturbation to induce 
physiological or pathological responses that are accompanied by gene expression changes.  
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This might explain the minimal findings at 6 weeks of age when mice have developed 
considerably from birth, but have yet to receive allergen exposure or the corresponding control 
treatment (saline).  At this time point, only 2 genes are recognized as having altered expression 
between the ETS-exposed and control groups.  Neither of these genes has direct ties to the innate 
or adaptive immune system and their responses, although some, as of yet, undiscovered link may 
be possible.  Respiratory perturbation at 6 weeks of age might reveal expression differences in 
genes induced by stress. 
 At 10 and 15 weeks of age, mice had received further respiratory system stress through 
OVA or saline aerosol and, in some cases, systemic OVA sensitization.  At both time points, 
significant alterations in gene expression were seen as a result of ETS exposure in utero.  The 
more challenged and manipulated 15-week old mice demonstrated the most pronounced changes.  
Even with fewer expression changes and the lack of physiological or pathological changes at 10 
weeks of age, altered gene expression related to ETS exposure is important due to the function of 
these genes in cellular stress, antigen presentation, and immune signaling.   
Gene expression changes seen at fifteen weeks of age are much more pronounced than 
those seen at 10 weeks of age and correlate very well with the histopathology and physiological 
changes seen at 15 weeks of age.  Many of these genes have previously established relationships 
to innate or adaptive immune responses.  The number of gene expression changes seen and the 
consistency of magnitude and direction of these changes suggest a non-random alteration of 
responses related to ETS exposure in utero.  Statistical analyses further support this conclusion 
via correlation coefficients and regression analyses.   
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CRITICAL THOUGHTS FOR FUTURE STUDIES 
Several steps could be taken to strengthen and further the results of this study:   
1) The exposure timing should be further investigated to determine whether the 
effect of ETS exposure is confined to the time of fetal lung development, or is 
more far-reaching. 
2) Given the minimal physical findings at early time points (prior to any additional 
respiratory exposures), the question of whether respiratory perturbation is 
necessary to unveil induced differences in response has arisen.  We are 
presently conducting further studies to address whether an inducement is 
needed to yield measurable differences in response. 
3) Many of the endpoint techniques have been improved and new equipment has 
been ordered that would undoubtedly provide stronger results within the same 
analyses.  This includes improved cytokine ELISA and RNA extraction 
protocols, refined plethysmosgraphy, new resistance-compliance equipment, 
and more proficient sampling techniques.  These things were all optimized as a 
result of this study but in some cases this optimization was only obtained after 
the fact.  For future studies continued improvement of techniques and protocols 
is critical. 
4) Consistency was a problem in the initial handling of gene expression data.  Initial 
RNA samples were processed through a different laboratory and on a different 
Affymetrix microarray than were the fifteen week samples, which provided the 
greatest amount of data.  The earlier samples were all lost after initial analysis 
and were not available for re-evaluation or confirmation testing.  Much of this 
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was unavoidable and a consequence of Hurricane Katrina and its impact on 
New Orleans which was the site of initial microarray analyses. 
5) Handling of raw gene expression data limited the scope and volume of 
conclusions concerning the impact of ETS exposure in utero.  By using very 
stringent filtering criteria, we limited false positive results.  However, given the 
nature of the exposures and the interaction of genes, it is inconceivable that we 
did not introduce a number of false negative results in each analysis.  In each 
analysis, and cumulatively, this limits the conclusions that can be made about 
the resultant data.  Many researchers now believe that in some cases fold-
changes as low as 1.2 may be significant if the changes are across multiple 
genes within a pathway.  This is especially true when evaluating mild to 
moderate changes in expression, such as those that would be expected from in 
utero or low-level environmental exposures.  Unlike the large expression 
changes in knockout/knockin mice or those associated with more severe insults 
or treatments, changes resulting from mild environmental exposures, such as 
those in our study, are expected to yield less dramatic expression changes and 
may only result in disorder or disease over a chronic period of time (as occurs 
in atherosclerosis, diabetes, and obesity).  In the future, enrichment programs 
could be used that would allow an enhanced evaluation of the up-regulation of 
critical processes and pathways and less emphasis on the behavior of or impact 
on individual genes. 
6) Although we did not detect sex differences in histopathology, BAL 
cytology/cytokines, or AHR in our studies, others have reported sex-based 
differences.  In non-ETS studies, we have detected an apparent increase in 
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AHR in males.  Given the inconsistency in the literature and in our own 
findings, the role of sex can not be dismissed as insignificant.  Since we had 
not detected sex-related differences in other endpoints, some of our gene 
expression studies involved only females.  Revisiting our gene studies, we find 
that inclusion of both sexes can make a difference in gene expression profiles.  
This supports the claim that sex-related differences in response (at least at the 
gene expression level) can occur.  We now are examining both sexes, together 
and independently, in gene expression analyses, as we have in analyses of our 
other endpoints. 
7) Increased proteomic-based interpretation of the outcome of altered gene 
expression would strengthen the biological relevance of these findings.  
Alternate transcriptional splicing, translational and post-translational 
modifications impact the relevance of gene expression changes.  This impact 
can be estimated by examining the actual changes in protein relative to changes 
in gene expression.  If these changes are not relatively similar, then non-
transcriptional and/or alternate transcriptional influences must be evaluated. 
 
In concluding, it needs to be pointed out that this study was very successful, resulting in 
peer-reviewed publications and acceptance into the body of literature on ETS and the growing 
literature on adult responses to in utero exposures.  However, there are many aspects of this 
study that could be improved, or new approaches attempted, as indicated above.  The basic 
mechanisms that translate ETS exposure in utero into measurable, long-term changes in immune 
responses are still a mystery and must be pursued.  The impact of this type of exposure on non-
immune, but potentially very significant, basic metabolic processes has not been examined but is 
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almost mandatory, given some of the gene expression changes seen following ETS exposure in 
utero (data not presented).   
 
 
 
 
 
 
 
 
95 
 
VITA 
 
 Rodney Lamar Rouse was born in Lake Charles, Louisiana, in January of 1957 to 
Roderick Lamar Rouse, Head of the Accounting Department at McNeese State University, and 
Anna Scarborough Rouse, housewife.  Rodney has one sibling, Roger, born in 1965.  Roderick 
succumbed to malignant melanoma in 1968 and the brothers were raised by their mother.   
Rodney graduated as salutatorian from Barbe High School in Lake Charles in 1975 and 
moved to Baton Rouge to attend Louisiana State University as a Top One Hundred Scholar.  
After three years in the animal science curriculum, Rodney was accepted into the Louisiana State 
University School of Veterinary Medicine where he served as the treasurer of the National 
Student Chapter of the American Veterinary Medical Association (1980-1982), performed as a 
summer fellow at the Northeast Regional Primate Center, Angell Memorial Hospital, and 
Harvard University in 1980, and graduated in the top ten percent of his class in 1982. 
Rodney practiced privately from 1982 to 2002, owning and operating a multi-location 
veterinary service organization supplying general and emergency veterinary care in the Baton 
Rouge area.  He returned to Louisiana State University in 1998 and received a Master of 
Business Administration degree in 2001.  In 2003, he again returned to Louisiana State 
University beginning this quest for a Doctor of Philosophy degree.  Over the years, Rodney 
produced four children and is married to Stella Manrique Rouse, who is beginning her career as 
an assistant professor of political science at the University of Maryland.  Rodney is pursuing a 
research position in the Washington, D. C. - Baltimore area. 
